Clinical Pharmacology Publications

Beard, M. E. J., Thwaites, J. H., Chambers, S. T., Colls, B. M., Doogue, M., Jeffery, M., … Pithie, A., … Sainsbury, R. (2005). Management guidelines for common medical conditions (11th ed.). Christchurch, NZ: Canterbury District Health Board, 271p.

Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott, L., … Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines List (8th ed.). Christchurch: The Caxton Press, 172p.

Frizelle, F., & Barclay, M. (2008). Constipation in adults. In C. Young (Ed.), Clinical evidence handbook: The international source of the best available evidence for effective health care. (pp. 167). UK: BMJ: Evidence Centre.

Stamp, L. K., Keating, P., Frampton, C., Barclay, M. L., Fanning, N., Millier, M., Hessian, P. A., & O'Donnell, J. L. (2024). Relationship between adalimumab concentrations, anti-drug antibodies and disease activity in rheumatoid arthritis: A cross-sectional observational study. Journal of Rheumatology, 51(3), 242-249. doi: 10.3899/jrheum.2023-0706

Sundermann, M., Clendon, O., McNeill, R., Doogue, M., & Chin, P. K. L. (2024). Optimising interruptive clinical decision support alerts for antithrombotic duplicate prescribing in hospital. International Journal of Medical Informatics, 186, 104418. doi: 10.1016/j.ijmedinf.2024.105418

Butler, J. M., Frampton, C. M., Moore, G., Barclay, M. L., & Jardine, D. L. (2023). Immediate effect of caffeine on sympathetic nerve activity: Why coffee is safe? A single-centre crossover study. Clinical Autonomic Research. Advance online publication. doi: 10.1007/s10286-023-00967-5

Campbell, P. O., Chin, P. K. L., Dalton, S. C., Metcalf, S. C. L., Douglas, N. M., & Chambers, S. T. (2023). Frequency of pharmacological target attainment with flucloxacillin and cefazolin in invasive methicillin-susceptible Staphylococcus aureus infection: A prospective cohort study in hospitalized patients. International Journal of Antimicrobial Agents, 61, 106695. doi: 10.1016/j.ijantimicag.2022.106695

Chin, P. K. L., Charles, K., Murnion, B., McGuire, T. M., Hilmer, S. N., Martin, J., Reith, D., … Doogue, M., … O'Mara, D. (2023). Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand. British Journal of Clinical Pharmacology, 89, 3105-3115. doi: 10.1111/bcp.15814

Drake, R., Prael, G., Phyo, Y., Chang, S., Hunt, J., Herbert, A., … Doogue, M., … Currow, D. (2023). Gabapentin for pain in pediatric palliative care. Journal of Pain & Symptom Management. Advance online publication. doi: 10.1016/j.jpainsymman.2023.11.011

Kee, P. S., Maggo, S. D. S., Kennedy, M. A., & Chin, P. K. L. (2023). The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses [Brief research report]. Frontiers in Pharmacology, 14, 1080117. doi: 10.3389/fphar.2023.1080117

Stamp, L. K., Horsley, C., Te Karu, L., Dalbeth, N., & Barclay, M. (2023). Colchicine: The good, the bad, the ugly, and how to minimise the risks. Rheumatology, kead625. Advance online publication. doi: 10.1093/rheumatology/kead625

Wang, M., Barclay, M. L., Chin, P. K. L., & Doogue, M. P. (2023). Changes in inpatient medicine prescribing during Covid-19 lockdown. Internal Medicine Journal, 53, 917-922. doi: 10.1111/imj.15996

Hussein, A., Digges, M., Chang, S., Hunt, J., Doogue, M., Rowett, D., … Currow, D. C. (2022). Pharmacovigilance in hospice/palliative care: Net effect of amitriptyline or nortriptyline on neuropathic pain: UTS/IMPACCT Rapid programme international consecutive cohort. Palliative Medicine, 36(6), 938-944. doi: 10.1177/02692163221085855

Kubovy, J., & Barclay, M. L. (2022). Helicobacter pylori in New Zealand: Current diagnostic trends and related costs. New Zealand Medical Journal, 135(1562), 48-55. Retrieved from https://journal.nzma.org.nz/

Liu, Z., Julsgaard, M., Zhu, X., Martin, J., Barclay, M., Cranswick, N., … Gearry, R., … the CARINA Study Group. (2022). Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. Journal of Crohn's & Colitis, 16, 1835-1844. doi: 10.1093/ecco-jcc/jjac093

Livirya, S., Pithie, A., Chua, I., Hamilton, N., Doogue, M., & Isenman, H. (2022). Oral amoxicillin challenge for low risk penicillin allergic patients. Internal Medicine Journal, 52, 295-300. doi: 10.1111/imj.14978

Palmer, D., Soule, S., Gaddam, R. R., Elder, P., Chambers, S., & Doogue, M. (2022). Unbound vitamin D concentrations are not decreased in critically ill patients. Internal Medicine Journal, 52, 89-94. doi: 10.1111/imj.15096

Seah, D. S. E., Wilcock, A., Chang, S., Sousa, M. S., Sinnarajah, A., Teoh, C. O., … Doogue, M., … Currow, D. C. (2022). Paracentesis for cancer-related ascites in palliative care: An international, prospective cohort study. Palliative Medicine, 36(9), 1408-1417. doi: 10.1177/02692163221122326

Spangehl, M. J., Clarke, H. D., Moore, G. A., Zhang, M., Probst, N. E., & Young, S. W. (2022). Higher tissue concentrations of Vancomycin achieved with low dose intraosseous injection versus intravenous despite limited tourniquet duration in primary TKA: A randomized trial. Journal of Arthroplasty, 37, 857-863. doi: 10.1016/j.arth.2022.01.057

Wallenburg, E., Brüggemann, R. J. M., Roberts, J. A., Jager, N. G. L., Ulldemolins, M., Wilkes, S., … Chin, P. K. L., & ter Heine, R. (2022). A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. Clinical Microbiology & Infection, 28, 446.e1-446.e7. doi: 10.1016/j.cmi.2021.06.039

Crake, R. L. I., Strother, M. R., Phillips, E., Doogue, M. P., Zhang, M., Frampton, C. M. A., Robinson, B. A., & Currie, M. J. (2021). Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: A patient feasibility study. Scientific Reports, 11(1), 5648. doi: 10.1038/s41598-021-85048-1

Drennan, P. G., Green, J. K., Gardiner, S. J., Metcalf, S. C. L., Kirkpatrick, C. M. J., Everts, R. J., Zhang, M., & Chambers, S. T. (2021). Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid. British Journal of Clinical Pharmacology, 87, 4684-4693. doi: 10.1111/bcp.14887

Everts, R. J., Gardiner, S. J., Zhang, M., Begg, R., Chambers, S. T., Turnidge, J., & Begg, E. J. (2021). Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers. Journal of Infection, 83, 182-189. doi: 10.1016/j.jinf.2021.05.037

McNeill, R. P., Zhang, M., Epton, M. J., & Doogue, M. P. (2021). Drub metabolism in severe chronic obstructive pulmonary disease: A phenotyping cocktail study. British Journal of Clinical Pharmacology, 87, 4397-4407. doi: 10.1111/bcp.14862

McNeill, R., Hanger, H. C., Chieng, J., & Chin, P. (2021). Polypharmacy in palliative care: Two deprescribing tools compared with a clinical review. Journal of Palliative Medicine, 24(5), 661-667. doi: 10.1089/jpm.2020.0225

Thomas, P. W. A., Chin, P. K. L., & Barclay, M. L. (2021). A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal, 51(3), 341-347. doi: 10.1111/imj.14778

Chambers, S. T., Long, M., Gardiner, S. J., Chin, P. K. L., Yi, M., Dalton, S. C., … Metcalf, S. C. L. (2020). Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion. International Journal of Antimicrobial Agents, 55, 105972. doi: 10.1016/j.ijantimicag.2020.105972

Chin, P. K. L., Chuah, Q., Crawford, A. M., Clendon, O. R., Drennan, P. G., Dalrymple, J. M., Barclay, M. L., & Doogue, M. P. (2020). Clinical decision support in a hospital electronic prescribing system informed by local data: Experience at a tertiary New Zealand centre. Internal Medicine Journal, 50, 1225-1232. doi: 10.1111/imj.14706

Chin, P. K. L., McNeill, R., Lee, H. K., Zhang, M., Jensen, B., Smith, M., & Doogue, M. P. (2020). Routine therapeutic drug monitoring of dabigatran: Experience at a tertiary center. Therapeutic Drug Monitoring, 42(3), 468-472. doi: 10.1097/ftd.0000000000000713

Everts, R. J., Begg, R., Gardiner, S. J., Zhang, M., Turnidge, J., Chambers, S. T., & Begg, E. J. (2020). Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers. Journal of Infection, 80, 42-53. doi: 10.1016/j.jinf.2019.09.004

Gardiner, S. J., Basevi, A. B., Hamilton, N. L., Metcalf, S. C. L., Chambers, S. T., Withington, S. G., Chin, P. K., Freeman, J. T., Dalton, S. C., on behalf of the Canterbury District Health Board Antimicrobial Stewardship Committee. (2020). Point prevalence surveys of antimicrobial use in adult inpatients at Canterbury District Health Board hospitals. New Zealand Medical Journal, 133(1525), 18-33. Retrieved from https://www.nzma.org.nz/journal

Gardiner, S. J., Metcalf, S. C. L., Werno, A., Doogue, M. P., Chambers, S. T., on behalf of the Canterbury District Health Board Antimicrobial Stewardship Committee. (2020). A persuasive approach to antimicrobial stewardship in Christchurch hospitals produced a sustained decrease in intravenous clarithromycin dosing and expenditure via a switch to azithromycin orally. New Zealand Medical Journal, 133(1512), 22-30. Retrieved from https://www.nzma.org.nz/journal

McCombie, A., Walmsley, R., Barclay, M., Ho, C., Langlotz, T., Regenbrecht, H., Gray, A., … Inns, S., & Schultz, M. (2020). A noninferiority randomized clinical trail of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory Bowel Diseases, 26(7), 1098-1109. doi: 10.1093/ibd/izz252

O'Grady, M., Clarke, L., Turner, G., Doogue, M., Purcell, R., Pearson, J., & Frizelle, F. (2020). Statin use and risk of acute diverticulitis: A population-based case-control study. Medicine, 99(20), e20264. doi: 10.1097/md.0000000000020264

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Merriman, T. R., Wright, D. F. B., … Dalbeth, N. (2020). Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response: In search of a minimum effective oxypurinol concentration. Clinical & Translational Science, 13, 110-115. doi: 10.1111/cts.12686

van Doorn, A. S., Meijer, B., Frampton, C. M. A., Barclay, M. L., & de Boer, N. K. H. (2020). Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Alimentary Pharmacology & Therapeutics, 52, 1276-1288. doi: 10.1111/apt.16036

Zhang, M., Moore, G. A., & Chin, P. K. L. (2020). Simultaneous determination of dabigatran, rivaroxaban, and apixaban in human plasma by liquid chromatography/tandem mass spectrometry. Therapeutic Drug Monitoring, 42(3), 473-480. doi: 10.1097/ftd.0000000000000744

Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2019). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 49, 513-518. doi: 10.1111/imj.14064

Brett, O. F., Brett, C. N., & Chin, P. K. L. (2019). The effect of routine preoperative interruption of dabigatran therapy on coagulation parameters and dabigatran plasma levels in a mixed surgical population. Anaesthesia & Intensive Care, 47(2), 183-188. doi: 10.1177/0310057x19841009

Currow, D. C., Ekström, M., Louw, S., Hill, J., Fazekas, B., Clark, K., … Doogue, M., … Agar, M. (2019). Sertraline in symptomatic chronic breathlessness: A double blind, randomised trial. European Respiratory Journal, 53, 1801270. doi: 10.1183/13993003.01270-2018

International Multiple Sclerosis Genetic Consortium, including Mason, D., & Barclay, M. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 365, eaav7188. doi: 10.1126/science.aav7188

Leggett, C., Giles, L., Anderson, J. J. A., Doogue, M., Couper, J., & Pena, A. S. (2019). Adherence to metformin is reduced during school holidays and weekends in children with type 1 diabetes participating in a randomised controlled trial. Archives of Disease in Childhood, 104, 890-894. doi: 10.1136/archdischild-2018-316303

McNeill, R., Chin, P., Coberger, E., & Doogue, M. (2019). A randomised controlled trial of patient information leaflets as a medication counselling aid. Internal Medicine Journal, 49(3), 328-332. doi: 10.1111/imj.14038

Romagnoni, A., Jégou, S., Van Steen, K., Wainrib, G., Hugot, J.-P., and International Inflammatory Bowel Disease Genetics Constortium (IIBDGC), including Barclay, M., Gearry, R., & Roberts, R. L. (2019). Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 9, 10351. doi: 10.1038/s41598-019-46649-z

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J., Zhang, M., Barclay, M., & Chapman, P. (2019). A pilot randomized controlled double-blind trial of high- versus low-dose weekly folic acid in people with rheumatoid arthritis receiving methotrexate. Journal of Clinical Rheumatology, 25(7), 284-287. doi: 10.1097/RHU.0000000000000848

Chambers, C. N. L., Frampton, C. M. A., McKee, M., & Barclay, M. (2018). 'It feels like being trapped in an abusive relationship': Bullying prevalence and consequences in the New Zealand senior medical workforce: A cross-sectional study. BMJ Open, 8(3), e020158. doi: 10.1136/bmjopen-2017-020158

Chin, P. K. L., Drennan, P. G., Gardiner, S. J., Zhang, M., Dalton, S. C., Chambers, S. T., & Begg, E. J. (2018). Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalised patients with Staphylococcus aureus bacteraemia. British Journal of Clinical Pharmacology, 84(10), 2311-2316. doi: 10.1111/bcp.13673

Chin, S. J., Moore, G. A., Zhang, M., Clarke, H. D., Spangehl, M. J., & Young, S. W. (2018). Intraosseous regional prophylaxis provides higher tissue concentrations in high BMI patients in total knee arthroplasty: A randomized trial. Journal of Arthroplasty, 33(7), S13-S18. doi: 10.1016/j.arth.2018.03.013

Gardiner, S. J., Drennan, P. G., Begg, R., Zhang, M., Green, J. K., Isenman, H. L., Everts, R. J., Chambers, S. T., & Begg, E. J. (2018). In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances. PLoS ONE, 13(7), e0199370. doi: 10.1371/journal.pone.0199370

Gardiner, S. J., Metcalf, S. C. L., Chin, P. K. L., Doogue, M. P., Dalton, S. C., & Chambers, S. T. (2018). Metronidazole stewardship initiative at Christchurch hospitals: Achievable with immediate benefits. New Zealand Medical Journal, 131(1473), 53-58. Retrieved from https://www.nzma.org.nz/journal

Momozawa, Y., Dmitrieva, J., Théātre, E., Deffontaine, V., Rahumouni, S., Charloteaux, B., … The International IBD Genetics Consortium, including Barclay, M., … Georges, M. (2018). IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 9(1), 2427. doi: 10.1038/s41467-018-04365-8

Munning-Schmidt, E., Zhang, M., Mulder, C. J., & Barclay, M. L. (2018). Late-onset rise of 6-MMP metabolites in IBD patients on azathioprine or mercaptopurine. Inflammatory Bowel Diseases, 24(4), 892-896. doi: 10.1093/ibd/izx081

Roberts, R. L., Wallace, M. C., Seinen, M. L., van Bodegraven, A. A., Krishnaprasad, K., Jones, G. T., van Rij, A. M., … Kennedy, M. A., … Gearry, R. B., … Barclay, M. (2018). Nonsynonymous polymorphism in guanine monophosphate synthetase is a risk factor for unfavorable thiopurine metabolite ratios in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 24(12), 2606-2612. doi: 10.1093/ibd/izy163

Slow, S., Epton, M., Storer, M., Thiessen, R., Lim, S., Wong, J., Chin, P., Tovaranonte, P., Pearson, J., Chambers, S. T., Murdoch, D. R., and VIDCAPS Group, including Jardine, D., & Pithie, A. (2018). Effect of adjunctive single high-dose vitamin D₃ on outcome of community-acquired pneumonia in hospitalised adults: The VIDCAPS randomised controlled trial. Scientific Reports, 8(1), 13829. doi: 10.1038/s41598-018-32162-2

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy, 20, 255. doi: 10.1186/s13075-018-1755-0

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 57(12), 2183-2189. doi: 10.1093/rheumatology/key237

Wright, D. F. B., Dalbeth, N., Phipps-Green, A. J., Merriman, T. R., Barclay, M. L., Drake, J., … Stamp, L. K. (2018). The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 84(5), 937-943. doi: 10.1111/bcp.13516

Zhang, M., Moore, G. A., Chin, P. K. L., Everts, R., & Begg, E. J. (2018). Simultaneous determination of Cefalexin, Cefazolin, Flucloxacillin and Probenecid by liquid chromatography-tandem mass spectrometry for total and unbound concentrations in human plasma. Therapeutic Drug Monitoring, 40(6), 682-692. doi: 10.1097/FTD.0000000000000555

Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal

Hernandez, I., Zhang, Y., Brooks, M. M., Chin, P. K. L., & Saba, S. (2017). Anticoagulation use and clinical outcomes after major bleeding on Dabigatran or Warfarin in atrial fibrillation. Stroke, 48(1), 159-166. doi: 10.1161/strokeaha.116.015150

Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 83(9), 2015-2026. doi: 10.1111/bcp.13307

Maggo, S. D. S., Chua, E. W., Chin, P., Cree, S., Pearson, J., Doogue, M., & Kennedy, M. A. (2017). A New Zealand platform to enable genetic investigation of adverse drug reactions. New Zealand Medical Journal, 130(1466), 62-69. Retrieved from http://www.nzma.org.nz/journal

Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., … IBD Sydney Organisation, and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46(11-12), 1037-1053. doi: 10.1111/apt.14368

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2017). Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics & Pharmacodynamics, 44(5), 415-423. doi: 10.1007/s10928-017-9530-4

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 76(9), 1522-1528. doi: 10.1136/annrheumdis-2016-210872

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases, 76(12), 2065-2070. doi: 10.1136/annrheumdis-2017-211873

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: A post hoc analysis of a randomized controlled trial. Arthritis Research & Therapy, 19(1), 283. doi: 10.1186/s13075-017-1491-x

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Chambers, C. N. L., Frampton, C. M. A., Barclay, M., & McKee, M. (2016). Burnout prevalence in New Zealand's public hospital senior medical workforce: A cross-sectional mixed methods study. BMJ Open, 6(11), e013947. doi: 10.1136/bmjopen-2016-013947

Chin, P. K. L., & Doogue, M. P. (2016). Long-term prescribing of new oral anticoagulants. Australian Prescriber, 39(6), 200-204. doi: 10.18773/austprescr.2016.068

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Huelsen, A., Fischer, J., Hegarty, J., Ashcroft, A., Frampton, C. M. A., & Barclay, M. L. (2016). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees: A randomised comparative trial. New Zealand Medical Journal, 129(1446), 53-63. Retrieved from http://www.nzma.org.nz/journal

Huelsen, A., Oumer, R., Ashcroft, A., Roberts, R. H., Coulter, G. N., Kelly, S. J., & Barclay, M. L. (2016). Achalasia: A 13-year, single-centre experience comparing endoscopic balloon dilation and laparoscopic Heller myotomy. New Zealand Medical Journal, 129(1433), 45-54. Retrieved from http://www.nzma.org.nz/journal

Khong, J. J., Burdon, K. P., Lu, Y., Laurie, K., Leonardos, L., Baird, P. N., … Doogue, M., … Craig, J. E. (2016). Pooled genome wide association detects association upstream of FCRL3 with Graves' disease. BMC Genomics, 17(1), 939. doi: 10.1186/s12864-016-3276-z

Lewis, B. C., Nair, P. C., Heran, S. S., Somogyi, A. A., Bowden, J. J., Doogue, M. P., & Miners, J. O. (2016). Warfarin resistance associated with genetic polymorphism of VKORC1: Linking clinical response to molecular mechamism using computational modeling. Pharmacogenetics & Genomics, 26(1), 44-50. doi: 10.1097/FPC.0000000000000184

McCombie, A., Langlotz, T., Barclay, M., Walmsley, R., Regenbrecht, H., & Schultz, M. (2016). Systematic review of IBD smartphone apps for symptom monitoring and communication with healthcare professionals. Journal of mHealth, 3(3), 36-41. Retrieved from http://www.thejournalofmhealth.com/

Sanderson, C., Quinn, S. J., Agar, M., Chye, R., Clark, K., Doogue, M., … Currow, D. C. (2016). Pharmacovigilance in hospice/palliative care: Net effect of pregabalin for neuropathic pain. BMJ Supportive & Palliative Care, 6(3), 323-330. doi: 10.1136/bmjspcare-2014-000825

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2016). Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 81(2), 277-289. doi: 10.1111/bcp.12799

Chew-Harris, J. S. C., Chin, P. K. L., Florkowski, C. M., George, P., & Endre, Z. (2015). Removal of body surface area normalisation improves raw-measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese. Internal Medicine Journal, 45(7), 766-773. doi: 10.1111/imj.12791

Chin, P. K. L., Chew-Harris, J. S. C., Florkowski, C. M., & Begg, E. J. (2015). The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance. British Journal of Clinical Pharmacology, 79(2), 268-277. doi: 10.1111/bcp.12501

Chinnaratha, M. A., Chaudhary, S., Doogue, M., McCormick, R. J., Woodman, R. J., & Wigg, A. J. (2015). Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis. Internal Medicine Journal, 45(12), 1230-1235. doi: 10.1111/imj.12866

Chua, E. W., Cree, S., Barclay, M. L., Doudney, K., Lehnert, K., Aitchison, A., & Kennedy, M. A. (2015). Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 15, 414-421. doi: 10.1038/tpj.2015.9

Dobinson, H. C., Anderson, T. P., Chambers, S. T., Doogue, M. P., Seaward, L., & Werno, A. M. (2015). Antimicrobial treatment options for granulomatous mastitis caused by Corynebacterium species. Journal of Clinical Microbiology, 53(9), 2895-2899. doi: 10.1128/jcm.00760-15

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Roberts, R. L., Fowler, E. V., Croft, A., … Barclay, M. L., Merriman, T. R., Gearry, R. B., … Radford-Smith, G. L. (2015). Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. Journal of Gastroenterology & Hepatology, 30(2), 299-307. doi: 10.1111/jgh.12674

Plajer, S. M., Chin, P. K. L., Vella-Brincat, J. W. A., Buffery, P. J., & Begg, E. J. (2015). Gentamicin and renal function: Lessons from 15 years' experience of a pharmacokinetic service for extended interval dosing of gentamicin. Therapeutic Drug Monitoring, 37(1), 98-103. doi: 10.1097/FTD.0000000000000107

Roberts, G. W., Quinn, S. J., Valentine, N., Alhawassi, T., O'Dea, H., Stranks, S. N., … Doogue, M. P. (2015). Relative hyperglycemia, a marker of critical illness: Introducing the Stress Hyperglycemia Ratio. Journal of Clinical Endocrinology & Metabolism, 100(12), 4490-4497. doi: 10.1210/jc.2015-2660

Roberts, R. L., & Barclay, M. L. (2015). Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 16(8), 891-903. doi: 10.2217/pgs.15.29

Saffian, S. M., Zhang, M., Chin, P. K. L., & Jensen, B. P. (2015). Quantification of dabigatran and indirect quantification of dabigatran acylglucuronides in human plasma by LC-MS/MS. Bioanalysis, 7(8), 957-966. doi: 10.4155/bio.15.32

Sanderson, C., Quinn, S. J., Agar, M., Chye, R., Clark, K., Doogue, M., … Currow, D. C. (2015). Pharmacovigilance in hospice/palliative care: Net effect of gabapentin for neuropathic pain. BMJ Supportive & Palliative Care, 5, 273-280. doi: 10.1136/bmjspcare-2014-000699

Buffery, P. J., Allen, K. M., Chin, P. K. L., Moore, G. A., Barclay, M. L., & Begg, E. J. (2014). Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: Can the strategy be improved? Therapeutic Drug Monitoring, 36(1), 86-92. doi: 10.1097/FTD.0b013e31829dc940

Chin, P. K. L., Patterson, D. M., Zhang, M., Jensen, B. P., Wright, D. F. B., Barclay, M. L., & Begg, E. J. (2014). Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 78(3), 630-638. doi: 10.1111/bcp.12366

Chin, P. K. L., Wright, D. F. B., Patterson, D. M., Doogue, M. P., & Begg, E. J. (2014). A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. British Journal of Clinical Pharmacology, 78(3), 599-609. doi: 10.1111/bcp.12364

Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014). Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs in R&D, 14(2), 113-123. doi: 10.1007/s40268-014-0045-9

Korell, J., Duffull, S. B., Dalrymple, J. M., Drake, J., Zhang, M., Barclay, M. L., & Stamp, L. K. (2014). Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 77(3), 493-497. doi: 10.1111/bcp.12209

Pan, S., Stamp, L. K., Duffull, S. B., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Korell, J. (2014). Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clinical Pharmacokinetics, 53(12), 1161-1170. doi: 10.1007/s40262-014-0179-5

Radhakutty, A., Shen, J., Hooper, A. J., Miller, S. A., Burnett, J. R., Mah, P. M., … Doogue, M. P. (2014). Quantification and genotyping of lipoprotein lipase in patients with diabetic lipaemia. Diabetic Medicine, 31(12), 1702-1707. doi: 10.1111/dme.12565

Snyder, B. D., Rowland, A., Polasek, T. M., Miners, J. O., & Doogue, M. P. (2014). Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European Journal of Clinical Pharmacology, 70(9), 1115-1122. doi: 10.1007/s00228-014-1716-8

Stamp, L. K., & Barclay, M. (2014). Therapeutic drug monitoring in rheumatic diseases: Utile or futile? Rheumatology, 53(6), 988-997. doi: 10.1093/rheumatology/ket355

Stamp, L. K., Merriman, T. R., Barclay, M. L., Singh, J. A., Roberts, R. L., Wright, D. F. B., & Dalbeth, N. (2014). Impaired response or insufficient dosage? Examining the potential causes of ”inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis & Rheumatism, 44(2), 170-174. doi: 10.1016/j.semarthrit.2014.05.007

Stamp, L. K., Turner, R., Khalilova, I. S., Zhang, M., Drake, J., Forbes, L. V., & Kettle, A. J. (2014). Myeloperoxidase and oxidation of uric acid in gout: Implications for the clinical consequences of hyperuricaemia. Rheumatology, 53(11), 1958-1965. doi: 10.1093/rheumatology/keu218

Zhang, M., Moore, G. A., & Young, S. W. (2014). Determination of vancomycin in human plasma, bone and fat by liquid chromatography/tandem mass spectrometry. Journal of Analytical & Bioanalytical Technique, 5(3), 1000196. doi: 10.4172/2155-9872.1000196

Zhang, M., Moore, G. A., Everts, R., & Begg, E. J. (2014). Determination of total and free concentrations of flucloxacillin and cefazolin in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Analytical & Bioanalytical Technique, 5(1), 1000182. doi: 10.4172/2155-9872.1000182

Beaudoin, M., Goyette, P., Boucher, G., Lo, K. S., Rivas, M. A., Stevens, C., … and also Barclay, M., Gearry, R., & Roberts, R. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9(9), e1003723. doi: 10.1371/journal.pgen.1003723

Burt, M. G., Mangelsdorf, B. L., Rogers, A., Ho, J. T., Lewis, J. G., Inder, W. J., & Doogue, M. P. (2013). Free and total plasma cortisol measured by immunoassay and mass spectrometry following ACTH_1-24 stimulation in the assessment of pituitary patients. Journal of Clinical Endocrinology & Metabolism, 98(5), 1883-1890. doi: 10.1210/jc.2012-3576

Chin, P. K. L., Florkowski, C. M., & Begg, E. J. (2013). The performances of the Cockcroft-Gault, Modification of Diet in Renal Disease Study and Chronic Kidney Disease Epidemiology Collaboration equations in predicting gentamicin clearance. Annals of Clinical Biochemistry, 50(6), 546-557. doi: 10.1177/0004563213492320

Chin, P. K. L., Vella-Brincat, J. W. A., Walker, S. L., Barclay, M. L., & Begg, E. J. (2013). Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 43(7), 778-783. doi: 10.1111/imj.12170

Crawford, G. B., Agar, M., Quinn, S. J., Phillips, J., Lister, C., Michael, N., Doogue, M., … Currow, D. C. (2013). Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for delirium. Journal of Palliative Medicine, 16(11), 1335-1341. doi: 10.1089/jpm.2013.0230

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2013). Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 19(39), 6656-6664. doi: 10.3748/wjg.v19.i39.6656

International Multiple Sclerosis Genetic Consortium (IMSGC), and also Mason, D., Barclay, M., Roberts, R., & Gearry, R. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 45(11), 1353-1360. doi: 10.1038/ng.2770

Kennedy, N. A., Asser, T. L., Mountifield, R. E., Doogue, M. P., Andrews, J. M., & Bampton, P. A. (2013). Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Internal Medicine Journal, 43(3), 278-286. doi: 10.1111/j.1445-5994.2012.02936.x

Koning, M., Ailabouni, R., Gearry, R. B., Frampton, C. M. A., & Barclay, M. L. (2013). Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study. Inflammatory Bowel Diseases, 19(4), 767-778. doi: 10.1097/MIB.0b013e31827f27c8

Korell, J., Stamp, L. K., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Duffull, S. B. (2013). A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clinical Pharmacokinetics, 52(6), 475-485. doi: 10.1007/s40262-013-0052-y

Nasir, B. F., Griffiths, L. R., Nasir, A., Roberts, R., Barclay, M., Gearry, R. B., & Lea, R. A. (2013). An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn’s disease cohort. Journal of Gastrointestinal Surgery, 17(9), 1643-1650. doi: 10.1007/s11605-013-2250-1

Nasir, B. F., Griffiths, L., Nasir, A., Roberts, R., Barclay, M., Gearry, R., & Lea, R. A. (2013). Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. Journal of Clinical Gastroenterology, 47(3), 242-245. doi: 10.1097/MCG.0b013e318258314d

Polasek, T. M., Patel, F., Jensen, B. P., Sorich, M. J., Wiese, M. D., & Doogue, M. P. (2013). Predicted metabolic drug clearance with increasing adult age. British Journal of Clinical Pharmacology, 75(4), 1019-1028. doi: 10.1111/j.1365-2125.2012.04446.x

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J. M., Zhang, M., & Chapman, P. T. (2013). Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis & Rheumatism, 65(6), 1636-1642. doi: 10.1002/art.37925

To, T. H. M., Agar, M., Shelby-James, T., Abernethy, A. P., Doogue, M., Rowett, D., … Currow, D. C. (2013). Off-label prescribing in palliative care: A cross-sectional national survey of palliative medicine doctors. Palliative Medicine, 27(4), 320-328. doi: 10.1177/0269216312464263

Van Egmond, R., Barclay, M. L., Chin, P. K. L., Sies, C. W., & Florkowski, C. M. (2013). Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place? Annals of Clinical Biochemistry, 50(5), 473-478. doi: 10.1177/0004563212473441

Wong, C., Kumar, S. S., Graham, G. G., Begg, E. J., Chin, P. K. L., Brett, J., … Day, R. O. (2013). Comparing dose prediction software used to manage gentamicin dosing. Internal Medicine Journal, 43(5), 519-525. doi: 10.1111/imj.12067

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2013). The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 69(7), 1411-1421. doi: 10.1007/s00228-013-1478-8

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2013). A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. Antimicrobial Agents & Chemotherapy, 57(1), 484-489. doi: 10.1128/aac.00768-12

Currow, D. C., Vella-Brincat, J., Fazekas, B., Clark, K., Doogue, M., & Rowett, D. (2012). Pharmacovigilance in hospice/palliative care: Rapid report of net clinical effect of metoclopramide. Journal of Palliative Medicine, 15(10), 1071-1075. doi: 10.1089/jpm.2012.0111

Eglinton, T. W., Barclay, M. L., Gearry, R. B., & Frizelle, F. A. (2012). The spectrum of perianal Crohn's disease in a population-based cohort. Diseases of the Colon & Rectum, 55(7), 773-777. doi: 10.1097/DCR.0b013e31825228b0

Eglinton, T. W., Roberts, R., Pearson, J., Barclay, M., Merriman, T. R., Frizelle, F. A., & Gearry, R. B. (2012). Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology, 107, 589-596. doi: 10.1038/ajg.2011.437

Ellis, E., Chin, P. K. L., Hunt, P. J., Lunt, H., Lewis, J. G., & Soule, S. G. (2012). Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with Type 2 diabetes? New Zealand Medical Journal, 125(1353). Retrieved from http://www.nzma.org.nz/journal

Jensen, B. P., Chin, P. K. L., Roberts, R. L., & Begg, E. J. (2012). Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. British Journal of Clinical Pharmacology, 74(5), 797-805. doi: 10.1111/j.1365-2125.2012.04259.x

Joseph, S. P., Ho, J. T., Doogue, M. P., & Burt, M. G. (2012). Perioperative management of the hypothalamic-pituitary-adrenal axis in patients with pituitary adenomas: An Australasian survey. Internal Medicine Journal, 42(10), 1120-1124. doi: 10.1111/j.1445-5994.2011.02582.x

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., … Gearry, R., … and also Barclay, M., & Roberts, R. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124. doi: 10.1038/nature11582

Roberts, R. L., & Barclay, M. L. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology & Hepatology, 27(10), 1546-1554. doi: 10.1111/j.1440-1746.2012.07220.x

Roberts, R. L., Gallo, L.-M. D., Barclay, M. L., Gómez-García, M., Cardeña, C., Merriman, T. R., Gearry, R. B., & Martin, J. (2012). Independent replication of an association of CNVR7113.6 with Crohn's disease in caucasians. Inflammatory Bowel Diseases, 18(2), 305-311. doi: 10.1002/ibd.21752

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Van Egmond, R., Chin, P., Zhang, M., Sies, C. W., & Barclay, M. L. (2012). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology & Therapeutics, 35(10), 1181-1189. doi: 10.1111/j.1365-2036.2012.05084.x

Vella-Brincat, J. W. A., Begg, E. J., Jensen, B. P., Chin, P. K. L., Roberts, R. L., Fairhall, M., … Reid, K. (2012). The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. Journal of Pain & Symptom Management, 43(3), 540-548. doi: 10.1016/j.jpainsymman.2011.04.022

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Anderson, C. A., Boucher, G., Lees, C. W., Franke, A., D’Amato, M., Taylor, K. D., … Barclay, M., … Roberts, R., … Gearry, R., … Rioux, J. D. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 43(3), 246-254. doi: 10.1038/ng.764

Bird, P. A., Murray, D. P., Zhang, M., & Begg, E. J. (2011). Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otology & Neurotology, 32(6), 933-936. doi: 10.1097/MAO.0b013e3182255933

Chin, P. K. L., Jensen, B. P., Larsen, H. S., & Begg, E. J. (2011). Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects. British Journal of Clinical Pharmacology, 72(6), 985-989. doi: 10.1111/j.1365-2125.2011.04036.x

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 17(11), 2287-2294. doi: 10.1002/ibd.21630

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Glubb, D. M., Gearry, R. B., Barclay, M. L., Roberts, R. L., Pearson, J., Keenan, J. I., McKenzie, J., & Bentley, R. W. (2011). NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 17(23), 2829-2837. doi: 10.3748/wjg.v17.i23.2829

Jensen, B. P., Chin, P. K. L., & Begg, E. J. (2011). Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS. Analytical & Bioanalytical Chemistry, 401(7), 2187-2193. doi: 10.1007/s00216-011-5303-x

Larsen, H. S., Chin, P. K. L., Begg, E. J., & Jensen, B. P. (2011). Quantification of total and unbound concentrations of lorazepam, oxazepam and temazepam in human plasma by ultrafiltration and LC-MS/MS. Bioanalysis, 3(8), 843-852. doi: 10.4155/bio.11.46

Morgan, A. R., Han, D.-Y., Lam, W.-J., Triggs, C. M., Fraser, A. G., Barclay, M., Gearry, R. B., … Ferguson, L. R. (2011). Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 72, 1117-1127. doi: 10.1016/j.humimm.2011.08.011

Rivas, M. A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., … International Inflammatory Bowel Disease Genetics Consortium, including Barclay, M., Gearry, R., Roberts, R., … Daly, M. J. (2011). Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 43(11), 1066-1073. doi: 10.1038/ng.952

Roberts, R. L., Hollis-Moffatt, J. E., Gómez-García, M., Fransen, K., Ponsioen, C. Y., Crusius, B. A., … Merriman, T. R., Barclay, M. L., Gearry, R. B., & Alizadeh, B. Z. (2011). Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 17(2), E19-E21. doi: 10.1002/ibd.21470

Rossin, E. J., Lage, K., Raychaudhuri, S., Xavier, R. J., Tatar, D., Benita, Y., International Inflammatory Bowel Disease Genetics Constortium, including Roberts, R., Barclay, M., Gearry, R., … Daly, M. J. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genetics, 7(1), e1001273. doi: 10.1371/journal.pgen.1001273

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including in those with renal impairment. Arthritis & Rheumatism, 63(2), 412-421. doi: 10.1002/art.30119

Zhang, M., Moore, G. A., Jensen, B. P., Begg, E. J., & Bird, P. A. (2011). Determination of dexamethasone and dexamethasone sodium phosphate in human plasma and cochlear perilymph by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B, 879(1), 17-24. doi: 10.1016/j.jchromb.2010.11.003

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2010). Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes & Immunity, 11, 509-514. doi: 10.1038/gene.2010.15

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. American Journal of Gastroenterology, 105(2), 354-359. doi: 10.1038/ajg.2009.582

Eglinton, T., Reilly, M., Chang, C., Barclay, M., Frizelle, F., & Gearry, R. (2010). Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. British Journal of Surgery, 97(7), 1103-1109. doi: 10.1002/bjs.7031

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., … Roberts, R., … Barclay, M., … Gearry, R., … Parkes, M. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12), 1118-1125. doi: 10.1038/ng.717

Gearry, R. B., Richardson, A. K., Frampton, C. M., Dodgshun, A. J., & Barclay, M. L. (2010). Population-based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology & Hepatology, 25, 325-333. doi: 10.1111/j.1440-1746.2009.06140.x

Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x

Roberts, R. L., Topless, R. K. G., Phipps-Green, A. J., Gearry, R. B., Barclay, M. L., & Merriman, T. R. (2010). Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes & Immunity, 11, 351-356. doi: 10.1038/gene.2010.11

Schultz, M., Gearry, R., Walmsley, R., Day, A. S., Fraser, A., Wyeth, J., Barclay, M., … Whiteside, C. (2010). New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease. New Zealand Medical Journal, 123(1314). Retrieved from http://journal.nzma.org.nz/journal/123-1314/4115/content.pdf

Simms, L. A., Doecke, J. D., Roberts, R. L., Fowler, E. V., Zhao, Z. Z., McGuckin, M. A., … McCallum, R., … Barclay, M. L., Gearry, R. B., Merriman, T. R., … Radford-Smith, G. L. (2010). KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. American Journal of Gastroenterology, 105, 2209-2217. doi: 10.1038/ajg.2010.161

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis & Rheumatism, 62(2), 359-368. doi: 10.1002/art.27201

Stewart, L. C., Day, A. S., Pearson, J., Barclay, M. L., Gearry, R. B., Roberts, R. L., & Bentley, R. W. (2010). SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World Journal of Gastroenterology, 16(45), 5727-5731. doi: 10.3748/wjg.v16.i45.5727

Triggs, C. M., Munday, K., Hu, R., Fraser, A. G., Gearry, R. B., Barclay, M. L., & Ferguson, L. R. (2010). Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research: Fundamental & Molecular Mechanisms of Mutagenesis, 690, 123-138. doi: 10.1016/j.mrfmmm.2010.01.020

Weersma, R. K., Crusius, J. B. A., Roberts, R. L., Koeleman, B. P. C., Palomino-Morales, R., Wolfkamp, S., Hollis-Moffatt, J. E., … Gearry, R. B., Barclay, M. L., … Merriman, T. R., … Alizadeh, B. Z. (2010). Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations. Inflammatory Bowel Diseases, 16(12), 2080-2089. doi: 10.1002/ibd.21342

Chin, P. K. L., Beckert, L. E. L., Gunningham, S., Edwards, A. L., & Robinson, B. A. (2009). Audit of anticoagulant thromboprophylaxis in hospitalized oncology patients. Internal Medicine Journal, 39(12), 819-825. doi: 10.1111/j.1445-5994.2008.01828.x

Doogue, M. P., Begg, E. J., Moore, M. P., Lunt, H., Pemberton, C. J., & Zhang, M. (2009). Metformin increases plasma ghrelin in Type 2 diabetes. British Journal of Clinical Pharmacology, 68(6), 875-882. doi: 10.1111/j.1365-2125.2009.03372.x

Ferguson, L. R., Han, D. Y., Huebner, C., Petermann, I., Barclay, M. L., Gearry, R. B., … Demmers, P. S. (2009). Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand Caucasian population. Gastroenterology Research & Practice, 591704. doi: 10.1155/2009/591704

Huebner, C., Browning, B. L., Petermann, I., Han, D. Y., Philpott, M., Barclay, M., Gearry, R., … Ferguson, L. R. (2009). Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflammatory Bowel Diseases, 15(12), 1784-1793. doi: 10.1002/ibd.21019

Huebner, C., Ferguson, L. R., Han, D. Y., Philpott, M., Barclay, M. L., Gearry, R. B., & et al (2009). Nucleotide-binding oligomerization domain containing I (NODI) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand Caucasian population: A case-control study. BMC Research Notes, 2, 52. doi: 10.1186/1756-0500-2-52

Petermann, I., Huebner, C., Browning, B. L., Gearry, R. B., Barclay, M. L., Kennedy, M., Roberts, R., … Han, D. Y., & Ferguson, L. R. (2009). Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 70, 440-446. doi: 10.1016/j.humimm.2009.03.002

Petermann, I., Triggs, C. M., Huebner, C., Han, D. Y., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2009). Mushroom intolerance: A novel diet-gene interaction in Crohn's disease. British Journal of Nutrition, 102(4), 506-508. doi: 10.1017/s0007114509276446

Schouten, B. J., Doogue, M. P., Soule, S. G., & Hunt, P. J. (2009). Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Annals of Clinical Biochemistry, 46(2), 167-169. doi: 10.1258/acb.2008.008151

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis & Rheumatism, 60(8), 2248-2256. doi: 10.1002/art.24653

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2009). Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B, 877(27), 3025-3030. doi: 10.1016/j.jchromb.2009.07.021

Bentley, R. W., Keenan, J. I., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2008). Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. American Journal of Gastroenterology, 103(5), 1168-1172. doi: 10.1111/j.1572-0241.2007.01742.x

Browning, B. L., Annese, V., Barclay, M. L., Bingham, S. A., Brand, S., Büning, C., … Gearry, R. B., … Witt, H. (2008). Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 45(1), 36-42. doi: 10.1136/jmg.2007.050773

Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 58(11), 3299-3308.

Ferguson, L. R., Browning, B. L., Huebner, C., Petermann, I., Shelling, A. N., Demmers, P., … Gearry, R. B., Barclay, M. L., & Philpott, M. (2008). Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive & Liver Disease, 40(9), 723-730. doi: 10.1016/j.dld.2008.02.011

Ferguson, L. R., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Demmers, P., … Han, D. Y. (2008). Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World Journal of Gastroenterology, 14(29), 4652-4661. doi: 10.3748/wjg.14.4652

Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M., & Barclay, M. L. (2008). Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clinical Gastroenterology & Hepatology, 6(6), 654-660. doi: 10.1016/j.cgh.2008.02.032

Gardiner, S. J., Gearry, R. B., Burt, M. J., Ding, S. L., & Barclay, M. L. (2008). Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. European Journal of Gastroenterology & Hepatology, 20(12), 1238-1242. doi: 10.1097/MEG.0b013e3282ffda37

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., … Barclay, M. L., & Kennedy, M. A. (2008). Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics & Genomics, 18(5), 434-438.

Roberts, R. L., Gearry, R. B., Kennedy, M. A., & Barclay, M. L. (2008). Beyond TPMT: Genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 5(3), 233-248. doi: 10.2217/17410541.5.3.233

Roberts, R. L., Hollis-Moffatt, J. E., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Merriman, T. R. (2008). Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes & Immunity, 9(6), 561-565. doi: 10.1038/gene.2008.49

Tarrant, K. M., Barclay, M. L., Frampton, C. M. A., & Gearry, R. B. (2008). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of inflammatory bowel disease phenotype. American Journal of Gastroenterology, 103(12), 3082-3093.

Bird, P. A., Begg, E. J., Zhang, M., Keast, A. T., Murray, D. P., & Balkany, T. J. (2007). Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otology & Neurotology, 28, 1124-1130.

Brooks, A. J., Begg, E. J., Zhang, M., Frampton, C. M., & Barclay, M. L. (2007). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Therapeutic Drug Monitoring, 29(5), 619-625.

Browning, B. L., Huebner, C., Petermann, I., Demmers, P., McCulloch, A., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2007). Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases, 13(9), 1069-1076.

Browning, B. L., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Shelling, A. N., & Ferguson, L. R. (2007). Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. American Journal of Gastroenterology, 102, 2504-2512.

Gearry, R. B., Roberts, R. L., Burt, M. J., Frampton, C. M. A., Chapman, B. A., Collett, J. A., Shirley, P., Allington, M. D. E., Kennedy, M. A., & Barclay, M. L. (2007). Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 13(10), 1220-1227.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 7(5), 312-317.

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. American Journal of Gastroenterology, 102, 2754-2761.

Vella-Brincat, J. W. A., Begg, E. J., Kirkpatrick, C. M. J., Zhang, M., Chambers, S. T., & Gallagher, K. (2007). Protein binding of cefazolin is saturable in vivo both between and within patients. British Journal of Clinical Pharmacology, 63(6), 753-757.

Cameron, R., Barclay, M., & Dobbs, B. (2006). Ambulatory oesophageal manometry and pH monitoring for investigation of chest pain: A New Zealand experience. New Zealand Medical Journal, 119(1230). Retrieved from http://journal.nzma.org.nz/journal/119-1230/1877/content.pdf

Chin, P., Hurrell, M., McGregor, D., & Beckert, L. (2006). The role of CT pulmonary angiography in patients with suspected pulmonary embolism admitted to general medicine. New Zealand Medical Journal, 119(1237). Retrieved from http://journal.nzma.org.nz/journal/119-1237/2052/content.pdf

Frizelle, F., & Barclay, M. (2006). Constipation in adults. Clinical Evidence, 15. Retrieved from http://clinicalevidence.bmj.com/ceweb/conditions/dsd/0413/0413.jsp

Gardiner, S. J., Doogue, M. P., Zhang, M., & Begg, E. J. (2006). Quantification of infant exposure to celecoxib through breast milk. British Journal of Clinical Pharmacology, 61(1), 101-104. doi: 10.1111/j.1365-2125.2005.02520.x

Gardiner, S. J., Gearry, R. B., Barclay, M. L., & Begg, E. J. (2006). Two cases of thiopurine methyltransferase (TPMT) deficiency: A lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology, 62(4), 473-476. doi: 10.1111/j.1365-2125.2005.02474.x

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2006). Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 62(4), 453-456.

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Burt, M. J., Chapman, B. A., & Barclay, M. L. (2006). High incidence of Crohn's disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflammatory Bowel Diseases, 12(10), 936-943.

Hughes, R. C., Gardiner, S. J., Begg, E. J., & Zhang, M. (2006). Effect of pregnancy on the pharmacokinetics of metformin. Diabetic Medicine, 23(3), 323-326. doi: 10.1111/j.1464-5491.2005.01769.x

Lewis, J. G., möpert, B., Shand, B. I., Doogue, M. P., Soule, S. G., Frampton, C. M., & Elder, P. A. (2006). Plasma variation of corticosteroid-binding globulin and sex hormone-binding globulin. Hormone & Metabolic Research, 38, 241-245.

Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M., Gearry, R. B., Barclay, M. L., Clark, D. W., & Hansen, P. (2006). Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics, 24(8), 767-781.

Vella-Brincat, J., Begg, E., Zhang, M., & Chambers, S. (2006). Cooling enhances benzylpenicillin stability during continuous home intravenous administration. Hospital Pharmacist, 13, 56-57.

Zhang, M., Moore, G. A., Gardiner, S. J., & Begg, E. J. (2006). Determination of celecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. Journal of Chromatography B, 830(2), 245-248. doi: 10.1016/j.jchromb.2005.10.048

Frizelle, F., & Barclay, M. (2005). Constipation in adults. Clinical Evidence, 14, 557-566.

Gardiner, S. J., Begg, E. J., Zhang, M., & Hughes, R. C. (2005). Transfer of rofecoxib into human milk. European Journal of Clinical Pharmacology, 61(5-6), 405-408.

Gearry, R. B., & Barclay, M. L. (2005). Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology & Hepatology, 20(8), 1149-1157.

Gearry, R. B., Barclay, M. L., Roberts, R. L., Harraway, J., Zhang, M., Pike, L. S., George, P. M., & Florkowski, C. M. (2005). Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice. Internal Medicine Journal, 35, 580-585.

Gearry, R., Barclay, M., Florkowski, C., George, P., & Walmsley, T. (2005). Faecal calprotectin: The case for a novel non-invasive way of assessing intestinal inflammation [Viewpoint]. New Zealand Medical Journal, 118(1214). Retrieved from http://journal.nzma.org.nz/journal/118-1214/1444/content.pdf

Huckabee, M. L., Butler, S. G., Barclay, M., & Jit, S. (2005). Submental surface electromyographic measurement and pharyngeal pressures during normal and effortful swallowing. Archives of Physical Medicine & Rehabilitation, 86(11), 2144-2149.

Sies, C., Florkowski, C., George, P., Gearry, R., Barclay, M., Harraway, J., … Walmsley, T. (2005). Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. New Zealand Medical Journal, 118(1210). Retrieved from http://journal.nzma.org.nz/journal/118-1210/1324/content.pdf

Frizelle, F. A., & Barclay, M. (2004). Constipation in adults. Clinical Evidence, 12, 610-622.

Frizelle, F. A., Gearry, R. B., Johnston, M., Barclay, M. L., Dobbs, B. R., Wise, C., & Troughton, W. D. (2004). Penile and clitoral stimulation for faecal incontinence: External application of a bipolar electrode for patients with faecal incontinence. Colorectal Disease, 6(1), 54-57. doi: 10.1111/j.1463-1318.2004.00543.x

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., & Chapman, B. A. (2004). Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology & Drug Safety, 13(8), 563-567.

Gearry, R. B., Roberts, R. L., Barclay, M. L., & Kennedy, M. A. (2004). Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics, 14(11), 779-781.

Gearry, R. B., Wakeman, C. J., Barclay, M. L., Chapman, B. A., Collett, J. A., Burt, M. J., & Frizelle, F. A. (2004). Surveillance for dysplasia in patients with inflammatory bowel disease: A national survey of colonoscopic practice in New Zealand. Diseases of the Colon & Rectum, 47(3), 314-322.

Leaper, M., Johnston, M. J., Barclay, M., Dobbs, B. R., & Frizelle, F. A. (2004). Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy, 36(6), 499-503.

Roberts, R. L., Barclay, M. L., Gearry, R. B., & Kennedy, M. A. (2004). A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clinica Chimica Acta, 341(1-2), 49-53.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2004). Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Molecular Diagnosis, 8(2), 101-105. doi: 10.1007/BF03260052

Vella-Brincat, J. W. A., Begg, E. J., Gallagher, K., Kirkpatrick, C. M. J., Zhang, M., Frampton, C., & Chambers, S. T. (2004). Stability of benzylpenicillin during continuous home intravenous therapy. Journal of Antimicrobial Chemotherapy, 53(4), 675-677. British Society for Antimicrobial Chemotherapy.

Zhang, M., Moore, G. A., Gardiner, S. J., & Begg, E. J. (2004). Determination of rofecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. Journal of Chromatography B, 807, 217-221. Elsevier.

Barclay, M. L., Sawyers, S. M., Begg, E. J., Zhang, M., Roberts, R., Kennedy, M. A., & Elliott, J. M. (2003). Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics, 13(10), 627-632.

Barclay, M., & Begg, E. (2003). The practice of digoxin therapeutic drug monitoring [Editorial]. New Zealand Medical Journal, 116(1187). Retrieved from http://journal.nzma.org.nz/journal/116-1187/704/content.pdf

Frizelle, F. A., & Barclay, M. L. (2003). Constipation in adults. Clinical Evidence. Retrieved from http://www.clinicalevidence.com/ceweb/conditions/dsd/0413/0413.jsp

Gardiner, S. J., Kirkpatrick, C., Begg, E. J., Zhang, M., Moore, M. P., & Saville, D. J. (2003). Transfer of metformin into human milk. Clinical Pharmacology & Therapeutics, 73, 71-77.

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., Chapman, B. A., Roberts, R., & Kennedy, M. A. (2003). Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 18, 395-400.

Howard, G., Barclay, M., Florkowski, C. M., Moore, G., & Roche, A. L. (2003). Lack of clinically significant interference by spironolactone with the AxSym Digoxin II assay. Therapeutic Drug Monitoring, 25(1), 112-113.

Sidwell, A., Barclay, M., Begg, E., & Moore, G. (2003). Digoxin therapeutic drug monitoring: An audit and review. New Zealand Medical Journal, 116(1187). Retrieved from http://journal.nzma.org.nz/journal/116-1187/708/content.pdf

Howard, G. W., Begg, E. J., Chambers, S. T., Vella-Brincat, J., Zhang, M., & Kirkpatrick, C. M. J. (2002). Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion. Journal of Antimicrobial Chemotherapy, 50, 429-432.

Owen, M., Pike, L. S., George, P. M., Barclay, M. L., & Florkowski, C. M. (2002). Macro-alkaline phosphatase due to IgG κ complex: Demonstration with polyethylene glycol precipitation and immunofixation. Annals of Clinical Biochemistry, 39, 523-525.

Zhang, M., Fawcett, J. P., & Shaw, J. P. (2002). Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. British Journal of Clinical Pharmacology, 54, 246-250.

Zhang, M., Moore, G. A., Lever, M., Gardiner, S. J., Kirkpatrick, C. M. J., & Begg, E. J. (2002). Rapid and simple high-performance liquid chromatographic assay for the determination of metformin in human plasma and breast milk. Journal of Chromatography B, 766(1), 175-179.

Barclay, M. L., & Begg, E. J. (2001). Aminoglycoside adaptive resistance. Importance for effective dosage regimens. Drugs, 61(6), 713-721.

Begg, E. J., Barclay, M. L., & Kirkpatrick, C. M. J. (2001). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 52(Suppl.), 35S-43S.

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R., & Barclay, M. L. (2001). Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? British Journal of Clinical Pharmacology, 51, 627-630.

Toumadre, J. P., Barclay, M. L., Fraser, R., Dent, J., Young, R., Berce, M., … Burnett, J. C. (2001). Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 96(8), 2418-2426.

Von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., … Eichelbaum, M. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology & Therapeutics, 70, 217-227.

Williams, J., Patsalos, P. N., Zhang, M., Schapel, G., Wilson, J. F., & Richens, A. (2001). Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Therapeutic Drug Monitoring, 23, 15-20.

Chapman, B. A., Burt, M. J., Frampton, C. M., Collett, J. A., Yeo, K. H. J., Wilkinson, I. D., … Barclay, M. L., … George, P. M. (2000). The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community. New Zealand Medical Journal, 113, 394-396.

Chapman, B. A., Burt, M. J., Frampton, C. M., Collett, J., Yeo, K. H. J., Wilkinson, I. D., … Barclay, M. L., … George, P. M. (2000). The prevalence of viral hepatitis (HAV, HBV & HCV) in the Christchurch community. New Zealand Medical Journal, 113(1118), 394-396.

Gardiner, S. J., Begg, E. J., Barclay, M. L., & Kirkpatrick, C. M. J. (2000). Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug Reactions & Toxicological Reviews, 19(4), 293-312.

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R. L., & Barclay, M. L. (2000). Cytochrome P450 2C9 genotype does not predict incidence of gastric bleeding with non steroidal anti-inflammatory drugs. Proceedings of ASCEPT, 7(April), 57.

Zhang, M., Fawcett, J. P., Kennedy, J. M., & Shaw, J. P. (2000). Stereoselective glucuronidation of formoterol by human liver microsomes. British Journal of Clinical Pharmacology, 49, 152-157.

Barclay, M. L. (1999). Helicobacter pylori update. New Ethicals Journal, 2(3), 35-40.

Barclay, M. L., Begg, E. J., Robson, R. A., Peters, W. A., & Ketelbey, J. W. (1999). Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Alimentary Pharmacology & Therapeutics, 13, 1215-1219.

Barclay, M. L., Kirkpatrick, C., & Begg, E. J. (1999). Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored? Clinical Pharmacokinetics, 36(2), 89-98.

Begg, E. J., Barclay, M. L., & Kirkpatrick, C. (1999). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 47, 23-30.

Jackson, N. W., Doogue, M. P., & Elliott, J. M. (1999). Priority points and cardiac events while waiting for coronary bypass surgery. Heart, 81(4), 367-373. doi: 10.1136/hrt.81.4.367

Menelaou, A., Somogyi, A. A., Barclay, M. L., & Bochner, F. (1999). Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Journal of Chromatography B: Biomedical Sciences & Applications, 731, 261-266.

Zhang, M., Fawcett, J. P., & Shaw, J. P. (1999). Rapid chiral high-performance liquid chromatographic assay for salmeterol and α-hydroxysalmeterol. Application to in vitro metabolism studies. Journal of Chromatography B: Biomedical Sciences & Applications, 729, 225-230.

Doogue, M. P., Choong, C. K., & Frizelle, F. A. (1998). Recurrent gallstone ileus. Australian & New Zealand Journal of Surgery, 68, 755-757.

Tournadre, J.-P., Barclay, M. L., Bouletreau, P., & Chassard, D. (1998). Lower oesophageal sphincter tone increases after induction of anaesthesia in pigs with full stomach. Canadian Journal of Anesthesia / Journal canadien d'anesthésie, 45(5 Part 1), 479-482.

Doogue, M. P., Brett, C. N. H., & Elliott, J. M. (1997). Life and death on the waiting list for coronary bypass surgery. New Zealand Medical Journal, 110(1037).

Bailey, R. R., Begg, E. J., Smith, A. H., Robson, R. A., Lynn, K. L., Chambers, S., Barclay, M. L., & Hornibrook, J. (1996). Prospective, randomised, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clinical Nephrology, 46, 183-186.

Barclay, M. L., Begg, E. J., Chambers, S. T., & Peddie, B. A. (1996). The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas Aeruginosa in vitro. Journal of Antimicrobial Chemotherapy, 38(5), 853-858.

Barclay, M. L., Begg, E. J., Chambers, S., Thornley, P. E., Pattemore, P. K., & Grimwood, K. (1996). Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 37, 1155-1164.

Barclay, M. L., Begg, E. J., Duffull, S. B., & Buttimore, R. C. (1995). Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Australian & New Zealand Journal of Medicine, 25, 230-235.

Chin, P. K. L., Than, M., & Chambers, S. (2023). One giant leap for cephalexin dosing, one small step for antimicrobial stewardship. Canadian Journal of Emergency Medicine, 25, 7-8. doi: 10.1007/s43678-022-00442-6

Crouwel, F., Simsek, M., van Doorn, A. S., Mulder, C. J. J., Buiter, H. J. C., Barclay, M. L., … de Boer, N. K. (2023). Rectally administrated thioguanine for distal ulcerative colitis: A multicenter case series [Brief report]. Inflammatory Bowel Diseases, 29, 1000-1004. doi: 10.1093/ibd/izac195

Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264

Kee, P. S., Maggo, S. D. S., Kennedy, M. A., Barclay, M. L., Miller, A. L., Lehnert, K., … Chin, P. K. L. (2022). Omeprazole treatment failure in gastroesophageal reflux disease and genetic variation at the CYP2C locus [Brief research report]. Frontiers in Genetics, 13, 869160. doi: 10.3389/fgene.2022.869160

Mortensen, J. S., Jensen, B. P., & Doogue, M. (2022). Pre-analytical stability of flucloxacillin, piperacillin, tazobactam, meropenem, cefalexin, cefazolin, and ceftazidime in therapeutic drug monitoring: A structured review. Therapeutic Drug Monitoring, 44(6), 709-719. doi: 10.1097/ftd.0000000000000975

Ng, J.-W., Tahir, N. A. M., Chin, P. K. L., Makmor-Bakry, M., & Mohd Saffian, S. (2022). A systematic review and meta-analysis of dabigatran peak and trough concentration in adults. British Journal of Clinical Pharmacology, 88, 4443-4459. doi: 10.1111/bcp.15431

Walter, T., Connor, S., Stedman, C., & Doogue, M. (2022). A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. British Journal of Clinical Pharmacology, 88, 1385-1386. doi: 10.1111/bcp.15039

Gardiner, S. J., Duffy, E. J., Chambers, S. T., Thomas, M. G., Addidle, M., Arnold, B., … Balm, M. N. D., … Berger, S., … Birch, M., Blackmore, T. K., Bloomfield, M., … Bupha-Intr, O., … Campbell, C., Chin, P. K. L., Dalton, S. C., … Douglas, N. M., … Elvy, J., Everts, R., … Hudson, B., … Isenman, H., Issa, M., Kelly, M. J., Li, C., … Maze, M., Metcalf, S. C. L., McCall, C., Murdoch, D., … Pithie, A., Raymond, N., … Ussher, J. E., … Walls, T., & Yew, H. S. (2021). Antimicrobial stewardship in human healthcare in Aotearoa New Zealand: Urgent call for national leadership and co-ordinated efforts to preserve antimicrobial effectiveness. New Zealand Medical Journal, 134(1544), 113-128. Retrieved from https://www.nzma.org.nz/journal

Wilkinson, T., Soule, S., & Doogue, M. (2021). Syndrome of inappropriate anti-diuretic hormone secondary to transient global amnesia. Internal Medicine Journal, 51(7), 1186-1187. doi: 10.1111/imj.15410

Falconer, N., Spinewine, A., Doogue, M. P., & Barras, M. (2020). Identifying medication harm in hospitalised patients: A bimodal, targeted approach. Therapeutic Advances in Drug Safety, 11, 1-5. doi: 10.1177/2042098620975516

Hunt, J., Brown, L., Fazekas, B., Doogue, M., Rowett, D., Luckett, T., … Currow, D. C. (2020). Evaluation of the IMPACCT Rapid Program: A cross-sectional survey of international site investigators. Journal of Palliative Care, 23(10), 1292-1293. doi: 10.1089/jpm.2020.0239

Kee, P. S., Chin, P. K. L., Kennedy, M. A., & Maggo, S. D. S. (2020). Pharmacogenetics of statin-induced myotoxicity. Frontiers in Genetics, 11, 575678. doi: 10.3389/fgene.2020.575678

McNeill, R. P., & Barclay, M. L. (2020). Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology, 55, 41-46. doi: 10.1016/j.coph.2020.09.006

Sinnappah, K. A., Kuan, I. H. S., Thynne, T. R. J., Doogue, M. P., & Wright, D. F. B. (2020). The pharmacokinetics of metformin in patients receiving intermittent haemodialysis [Short report]. British Journal of Clinical Pharmacology, 86, 1430-1443. doi: 10.1111/bcp.14244

Coller, J. K., Ramachandran, J., John, L., Tuke, J., Wigg, A., & Doogue, M. (2019). The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome [Short report]. British Journal of Clinical Pharmacology, 85, 2170-2175. doi: 10.1111/bcp.14034

de Boer, N. K. H., on behalf of the Thiopurine Working Group, including Barclay, M. L., & Gearry, R. B. (2019). Thiopurine therapy in inflammatory bowel diseases: Making new friends should not mean losing old ones. Gastroenterology, 156, 11-19. doi: 10.1053/j.gastro.2018.11.039

Khan, A., Boyke Berahmana, A., Day, A. S., Barclay, M. L., & Schultz, M. (2019). New Zealand Society of Gastroenterology guidelines on therapeutic drug monitoring in inflammatory bowel disease. New Zealand Medical Journal, 132(1491), 46-62. Retrieved from https://www.nzma.org.nz/journal

Mortensen, J. S., Jensen, B. P., Zhang, M., & Doogue, M. (2019). Pre-analytical stability of piperacillin, tazobactam, meropenem and ceftazidime in plasma and whole blood using LC-MS/MS [Short communication]. Therapeutic Drug Monitoring, 41(4), 538-543. doi: 10.1097/ftd.0000000000000650

Barclay, M. L., & Stamp, L. K. (2018). Vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease [Invited]. Alimentary Pharmacology & Therapeutics, 47(4), 535-536. doi: 10.1111/apt.14465

Drennan, P., Doogue, M., van Hal, S. J., & Chin, P. (2018). Bayesian therapeutic drug monitoring software: Past, present and future. International Journal of Pharmacokinetics, 3(4), 109-114. doi: 10.4155/ipk-2018-0005

Okamura-Kho, A., Chuah, Q., Chin, P., & Doogue, M. (2018). Rarely a triple whammy in general medicine. New Zealand Medical Journal, 1476(131), 92-95. Retrieved from https://www.nzma.org.nz/journal

Polasek, T. M., Doogue, M. P., & Thynne, T. R. J. (2018). Metformin treatment of type 2 diabetes mellitus in pregnancy: Update on safety and efficacy. Therapeutic Advances in Drug Safety, 9(6), 287-295. doi: 10.1177/2042098618769831

Stamp, L. K., & Barclay, M. L. (2018). How to prevent allopurinol hypersensitivity reactions? Rheumatology, 57(1), i35-i41. doi: 10.1093/rheumatology/kex422

Stamp, L. K., Merriman, T., Frampton, C., Zhang, M., Wallace, M., Miner, J. N., & Dalbeth, N. (2018). Plasma oxypurinol as a measure of adherence in clinical trials. Annals of the Rheumatic Diseases, 77(2), 313-314. doi: 10.1136/annrheumdis-2016-210661

Chin, P. K. L., Fox, A. L., Marais, M., & Tiong, J. H. T. (2016). Screening coagulation tests are underutilised in patients on dabigatran presenting with thromboembolic or haemorrhagic events. Internal Medicine Journal, 46(2), 240-241. doi: 10.1111/imj.12970

Watts, G. J., Clark, K., Agar, M., Davidson, P. M., McDonald, C., Lam, L. T., … Doogue, M., … on behalf of the Australian national Palliative Care Clinical Studies Collaborative (PaCCSC). (2016). Study protocol: A phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. BMJ Open, 6(11), e013177. doi: 10.1136/bmjopen-2016-013177

Chin, P. K. L. (2015). Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants? Seminars in Thrombosis & Hemostasis, 41(2), 195-207. doi: 10.1055/s-0035-1546465

Clark, K., Quinn, S. J., Doogue, M., Sanderson, C., Lovell, M., & Currow, D. C. (2015). Routine prescribing of gabapentin or pregabalin in supportive and palliative care: What are the comparative performances of the medications in a palliative care population? Supportive Care in Cancer, 23(9), 2517-2520. doi: 10.1007/s00520-015-2837-z

Chin, P. K. L., & Wright, D. F. B. (2014). [Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis"]. Circulation, 130(22), e194. doi: 10.1161/circulationaha.114.010099

Chin, P. K. L., Wright, D. F. B., & Begg, E. J. (2014). Dabigatran in patients with mechanical heart valves. New England Journal of Medicine, 370, 382-383. doi: 10.1056/NEJMc1315004

Chin, P. K. L., Wright, D. F. B., Doogue, M. P., & Begg, E. J. (2014). Learning more from the dabigatran concentrations in RE-LY. JACC, 63(24), 2746-2747. doi: 10.1016/j.jacc.2013.11.069

Doogue, M. P. (2014). A safe and effective drug? New Zealand Medical Journal, 127(1404). Retrieved from http://www.nzma.org.nz/journal

Roberts, R. L., Wallace, M. C., Seinen, M. L., Krishnaprasad, K., Chew, A., Lawrance, I., … Barclay, M. L. (2014). PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. American Journal of Gastroenterology, 109, 925-927. doi: 10.1038/ajg.2014.89

Upton, T. J., Hunt, P. J., & Doogue, M. P. (2014). Hyponatraemic seizure following arginine vasopressin for von Willebrand disease: Pernicious, predictable and preventable. Internal Medicine Journal, 44(5), 521-522. doi: 10.1111/imj.12404

Chin, P. K. L., Barclay, M. L., & Begg, E. J. (2013). Rifampicin and dabigatran etexilate: A place for laboratory coagulation monitoring. British Journal of Clinical Pharmacology, 75(2), 554-555. doi: 10.1111/j.1365-2125.2012.04408.x

Doogue, M. P., & Polasek, T. M. (2013). The ABCD of clinical pharmacokinetics. Therapeutic Advances in Drug Safety, 4(1), 5-7. doi: 10.1177/ 2042098612469335

Doogue, M. P., & Thynne, T. R. J. (2013). Product information for generic drugs: Old, unloved and sometimes unsafe. Internal Medicine Journal, 43(12), 1346-1348. doi: 10.1111/imj.12295

Doogue, M. P., & Thynne, T. R. J. (2013). What is quality of medicines? Internal Medicine Journal of Thailand, 43(10), 1057-1058. doi: 10.1111/imj.12263

Fazal, M. W., Doogue, M. P., Leong, R. W., Bampton, P. A., & Andrews, J. M. (2013). Allopurinol use in pregnancy in three women with inflammatory bowel disease: Safety and outcomes: A case series. BMC Gastroenterology, 13, 172. doi: 10.1186/1471-230X-13-172

Howey, O. K., & Chin, P. K. L. (2013). Usage of renal function equations to guide prescribing in general medicine. New Zealand Medical Journal, 126(1383). Retrieved from http://www.nzma.org.nz/journal

Jones, G. R. D., Bryant, S., Fullinfaw, R., Ilett, K., Miners, J. O., Morris, R. G., & Doogue, M. P. (2013). Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. Medical Journal of Australia, 198, 368-369. doi: 10.5694/mja12.10366

Phillips, C. J., Doan, H., Kirkpatrick, C. M. J., Gordon, D. L., & Doogue, M. P. (2013). An educational intervention to improve vancomycin prescribing and monitoring. International Journal of Antimicrobial Agents, 41(4), 393-394. doi: 10.1016/j.ijantimicag.2012.11.010

Thynne, T. R. J., & Doogue, M. P. (2013). A dose of paracetamol for the levothyroxine absorption test. Clinical Endocrinology, 78(6), 968-969. doi: 10.1111/cen.12211

Begg, E. J., & Chin, P. K. L. (2012). A unified pharmacokinetic approach to individualized drug dosing. British Journal of Clinical Pharmacology, 73(3), 335-339. doi: 10.1111/j.1365-2125.2011.04089.x

Campbell, K. A., Joseph, S. P., Whiting, M. J., & Doogue, M. P. (2012). The half-lives of plasma free metanephrines. Clinical Endocrinology, 76, 764-766. doi: 10.1111/j.1365-2265.2011.04273.x

Campbell, K., & Doogue, M. (2012). Evaluating and managing patients with thyrotoxicosis. Australian Family Physician, 41(8), 564-572. [Case Study].

Chin, P. K. L., Vella-Brincat, J. W. A., & Begg, E. J. (2012). Clarifying the American Society of Clinical Oncology Practice Guideline for Chemotherapy Dosing in Obese Adults. Journal of Clinical Oncology, 30(31), 3897. doi: 10.1200/JCO.2012.44.1626

Chin, P. K. L., Vella-Brincat, J. W. A., Barclay, M. L., & Begg, E. J. (2012). Perspective on dabigatran etexilate dosing: Why not follow standard pharmacological principles? British Journal of Clinical Pharmacology, 74(5), 734-740. doi: 10.1111/j.1365-2125.2012.04266.x

Currow, D. C., Rowett, D., Doogue, M., To, T. H. M., & Abernethy, A. P. (2012). An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. Journal of Palliative Medicine, 15(3), 282-286. doi: 10.1089/jpm.2012.9605

Fairhall, M., Reid, K., Vella-Brincat, J. W. A., Walker, J., Chin, P. K. L., Jensen, B. P., … Begg, E. J. (2012). Exploring hospice patients' views about participating in research. Journal of Pain & Symptom Management, 43(3), e9-e11. doi: 10.1016/j.jpainsymman.2011.04.013

Snyder, B., Polasek, T. M., & Doogue, M. P. (2012). Reply to: Graefe-Mody U, Friderich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946. Diabetes, Obesity & Metabolism, 14(7), 670. doi: 10.1111/j.1463-1326.2012.01588.x

Vella-Brincat, J., McKean, A., & Barclay, M. (2011). Clozapine-induced gastrointestinal hypomotility [Letter]. Australasian Psychiatry, 19(5), 450-451. doi: 10.3109/10398562.2011.610462

Gearry, R. B., Day, A. S., Barclay, M. L., Leong, R. W. L., & Sparrow, M. P. (2010). Azathioprine and allopurinol: A two-edged interaction [Editorial]. Journal of Gastroenterology & Hepatology, 25(4), 653-655. doi: 10.1111/j.1440-1746.2010.06254.x

Hollis-Moffatt, J. E., Gearry, R. B., Barclay, M. L., Merriman, T. R., & Roberts, R. L. (2010). Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease [Letter]. American Journal of Gastroenterology, 105(5), 1204-1205. doi: 10.1038/ajg.2010.34

Roberts, R. L., Gearry, R. B., & Barclay, M. L. (2010). Allopurinol—thiopurine combination therapy in inflammatory bowel disease: Are there genetic clues to this puzzle? [Editorial]. Pharmacogenomics, 11(11), 1505-1508. doi: 10.2217/pgs.10.143

Roberts, R. L., Zhang, M., Marinaki, A. M., & Stamp, L. K. (2010). Does genetic variability in aldehyde oxidase and molybdenum cofactor sulfurase predict nonresponse to allopurinol? [Letter to the editors]. Alimentary Pharmacology & Therapeutics, 32(2), 310-311. doi: 10.1111/j.1365-2036.2010.04349.x

Stamp, L. K., O'Donnell, J. L., Barclay, M. L., Frampton, C., & Chapman, P. T. (2010). Response to comments [Letter to the editor]. Arthritis & Rheumatism, 62(8), 2560-2561. doi: 10.1002/art.27539

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Barclay, M. L., Kennedy, M. A., Frampton, C. M. A., & Roberts, R. L. (2009). Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to longterm therapy with methotrexate response in rheumatoid arthritis [Letter]. Annals of the Rheumatic Diseases, 68(1), 154-155. doi: 10.1136/ard.2008.089383

Gardiner, S. J., Kirkpatrick, C. M. J., Zhang, M., & Begg, E. J. (2008). Cimetidine does not appear to influence the distribution of metformin into human milk [Letter to the editor]. British Journal of Clinical Pharmacology, 66(4), 564-565. doi: 10.1111/j.1365-2125.2008.03190.x

Sung, E. Y. Y., Moore, M. P., Lunt, H., Doogue, M., Zhang, M., & Begg, E. J. (2008). Do thiazide diuretics alter the pharmacokinetics of metformin in patients with type 2 diabetes already established on metformin? [Letter to the editor]. British Journal of Clinical Pharmacology, 67(1), 130-131. doi: 10.1111/j.1365-2125.2008.03302.x

Doogue, M., Soule, S., & Hunt, P. (2007). Another cause of 'pseudophaeochromocytoma': Quetiapine associated with a false positive normetanephrine result. Clinical Endocrinology, 67, 472-476.

Gardiner, S. J., Begg, E. J., Sau, A., Marinaki, A., Gearry, R. B., & Barclay, M. L. (2007). Thiopurine treatment in inflammatory bowel disease [Letter to the editor]. Clinical Pharmacokinetics, 46(9), 803-804.

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2007). Breast-feeding during maternal use of azathioprine [Comment]. Annals of Pharmacotherapy, 41(4), 719-720.

Gearry, R. B., Lea, R. A., Roberts, R. L., Chambers, G. K., Barclay, M. L., & Kennedy, M. A. (2006). CARD15 allele frequency differences in New Zealand Maori: Ancestry specific susceptibility to Crohn's disease in New Zealand? [Letter]. Gut, 55, 580. doi: 10.1136/gut.2005.085464

Stamp, L., Roberts, R., Kennedy, M., Barclay, M., O'Donnell, J., & Chapman, P. (2006). The use of low dose methotrexate in rheumatoid arthritis: Are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomedicine & Pharmacotherapy, 60, 678-687.

Doogue, M. P., Begg, E. J., & Bridgman, P. (2005). Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clinic Proceedings, 80(10), 1368-1370.

Gearry, R. B., Aitken, J. M., Roberts, R. L., Ismail, S. L., Keenan, J., & Barclay, M. L. (2005). Gastrointestinal: Mycobacterium avium paratuberculosis and Crohn's disease. Journal of Gastroenterology & Hepatology, 20(12), 1943. doi: 10.1111/j.1440-1746.2005.04187.x

Doogue, M. P., Gardiner, S. J., & Begg, E. J. (2004). Comment: Prediction of milk/plasma concentration ratio of drugs. Annals of Pharmacotherapy, 38(1), 174-175.

Doogue, M. P., Gardiner, S. J., & Begg, E. J. (2004). Comment: Prediction of milk/plasma concentration ratio of drugs [Letter]. Annals of Pharmacotherapy, 38, 174-175.

Frizelle, F., & Barclay, M. (2004). Who misses the cancers at colonoscopy? Reply to Fracasso et al [Letter to the editor]. Endoscopy, 36, 1126-1127.

Barclay, M. L. (2003). 'Steakhouse syndrome' medical management. New Ethicals Journal, 6(11), 39.

Gearry, R., Barclay, M., Gardiner, S., & Zhang, M. (2003). 6-thioguanine nucleotides and thiopurine methyltransferase activity: Important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP [Letter]. New Zealand Medical Journal, 116(1178). Retrieved from http://journal.nzma.org.nz/journal/116-1178/531/content.pdf

Stedman, C. A. M., & Barclay, M. L. (2000). Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 14(8), 963-978. doi: 10.1046/j.1365-2036.2000.00788.x

Zhang, M., Fawcett, J. P., Kennedy, J. M., & Shaw, J. P. (2000). [Review of the book Stereoselective glucuronidation of salbutamol by human liver microsomes]. Journal of Clinical Pharmacology, 49. [Book Review].

Kamel, K. S., Chin, P. K. L., Doogue, M. P., & Barclay, M. L. (2017). Comment on: "Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study>". Clinical Pharmacokinetics, 56(2), 207-208. doi: 10.1007/s40262-016-0481-5

Johnson, D. W., Jones, G. R. D., Mathew, T. H., Ludlow, M. J., Doogue, M. P., Jose, M. D., … Australasian Creatinine Consensus Working Group. (2012). Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: New developments and revised recommendations [Position statement]. Medical Journal of Australia, 197(4), 222-223. doi: 10.5694/mja11.11329

Bentley, R. W., Keown, D., Merriman, T. R., Krishnan, M. R., Gearry, R. B., Barclay, M. L., Roberts, R. L., & Day, A. S. (2011). Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males [Letter to the editor]. Alimentary Pharmacology & Therapeutics, 33(7), 855-856. doi: 10.1111/j.1365-2036.2011.04588.x

Kirkpatrick, C. M. J., Begg, E. J., Barclay, M. L., & Duffull, S. B. (2002). Aminoglycoside dosage regimens after therapeutic drug monitoring. Clinical Pharmacokinetics, 41(10), 791-792.

Ross, A. G., & Barclay, M. L. (2002). Treatment of irritable bowel syndrome. New Ethicals Journal, 5(4), 37-42. New Zealand: Adis International.

Young, S. W., Zhang, M., Moore, G. A., Pitto, R. P., Clarke, H. D., & Spangehl, M. J. (2018). The John N. Insall Award: Higher tissue concentrations of vancomycin achieved with intraosseous regional prophylaxis in revision TKA: A randomized controlled trial. Clinical Orthopaedics & Related Research, 476(1), (pp. 66-74). doi: 10.1007/s11999.0000000000000013

Young, S. W., Zhang, M., Freeman, J. T., Mutu-Grigg, J., Pavlou, P., & Moore, G. A. (2014). The Mark Coventry Award: Higher tissue concentrations of vancomycin with low-dose intraosseous regional versus systemic prophylaxis in TKA: A randomised trial. Clinical Orthopaedics & Related Research, 472(1), (pp. 57-65). doi: 10.1007/s11999-013-3038-z

Young, S. W., Zhang, M., Freeman, J. T., Vince, K. G., & Coleman, B. (2013). Higher cefazolin concentrations with intraosseous regional prophylaxis in TKA. Clinical Orthopaedics & Related Research, 471(1), (pp. 244-249). doi: 10.1007/s11999-012-2469-2

Barclay, M. L., Sawyers, S. M., Begg, E. J., Roberts, R. L., Kennedy, M. A., & Elliott, J. M. (2001). Correlation of CYP450 2D6 genotype withperhexiline phenotypic metaboliser status. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 9, (pp. 111). [Full Paper]

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com

Barclay, M. L., Ovenden, C., Anderson, A., & Chou, E. (2023). Thioguanine efficacy, safety and TDM in IBD patients in New Zealand. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P514. Retrieved from https://www.asceptasm.com

Chin, P. K. L., O'Mahoney, A., & Hiskett, I. (2023). Routine therapeutic drug monitoring of rivaroxaban: Experience at a tertiary center. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P509. Retrieved from https://www.asceptasm.com

Doogue, M. P. (2023). Clinical decision support in prescribing systems to mitigate risks from pharmacokinetic drug-drug interactions. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 313. Retrieved from https://www.asceptasm.com

Morahan, M.-C., Yorkston, D., Knight, J., Borrie, T., Hastie, B., & Chin, P. (2023). The Covid-19 pandemic perspective from a New Zealand medicines information service. Pharmacy Education, 23(6), (pp. 176-177). doi: 10.46542/pe.2023.236.158191

Pairman, L., Chin, P., McNeill, R., & Doogue, M. (2023). The effect of compulsory indications in electronic hospital prescriptions on prescriber behaviour. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 435. Retrieved from https://www.asceptasm.com

Zhang, M., Moore, G., Chin, P. K. L., & Doogue, M. (2023). An efficient HILIC-MS/MS method for monitoring metformin in human plasma. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P510. Retrieved from https://www.asceptasm.com

Kerse, K. E. G., & Doogue, M. (2022). Prescribing patterns in very elderly inpatients in Christchurch, New Zealand. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 516. Retrieved from https://www.asceptasm.com

Morahan, M.-C., Campbell, V., Selagan, N., Houghton, K., Gardiner, S., & Chin, P. (2022). Vanquish the vancomycin trough: The AUC strikes back. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 543. Retrieved from https://www.asceptasm.com

Pairman, L., McNeill, R., Chin, P., & Doogue, M. (2022). Using electronic prescription and laboratory data to assess prescribing practice. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 111. Retrieved from https://www.asceptasm.com

Shaw, A. M., Chin, P. K., & Wright, D. F. B. (2022). Vancomycin AUC optimisation using minimal plasma concentration monitoring. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 555. Retrieved from https://www.asceptasm.com

Maggo, S., Kee, J., Hitchman, L., Chin, P., Doogue, M., Miller, A., … Kennedy, M. (2021). Assessing the pharmacogenomic landscape of adverse drug reactions in Aotearoa [Invited]. Proceedings of the Genetics Otago (GO) Annual Symposium. Retrieved from https://blogs.otago.ac.nz/go

Mules, T., Stedman, C. A., Ding, S., Burt, M., Gearry, R., Chalmers-Watson, T., Falvey, J., Chapman, B., Barclay, M. L., Lim, G., … Ngu, J. H. (2020). The ABC score accurately predicts mortality in hospitalized patients that develop upper gastrointestinal bleeding. Gastrointestinal Endoscopy, 91(6, Suppl.), (pp. AB590-AB591). doi: 10.1016/j.gie.2020.03.3668

Doogue, M. P., & Chin, P. K. L. (2019). Using patient simulation in the clinical learning environment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 59). Retrieved from https://www.asceptasm.com

Drennan, P., Green, J., Gardiner, S., Metcalf, S., Kirkpatrick, C., Zhang, M., & Chambers, S. (2019). Clinical outcomes and pharmacokinetic-pharmacodynamic target attainment in patients treated with oral flucloxacillin plus probenecid for staphylococcal infections. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 22). Retrieved from https://www.asceptasm.com

Liu, W., Liau, Y., Maggo, S., Doogue, M., & Kennedy, M. (2019). Exploring combinatorial genetic contributions to a serious adverse drug reaction. Proceedings of the MapNet Meeting. (pp. 28). Retrieved from http://mapnet2019.nz/

McNeill, R., Hanger, C., Chieng, J., & Chin, P. (2019). Polypharmacy in palliative care: A retrospective comparison of two explicit deprescribing tools. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 22). Retrieved from https://www.asceptasm.com

Morahan, M.-C., Coberger, E., Stedman, C., & Doogue, M. (2019). Validity and reliability of clinical resources on adverse effects of medicines: Drug-induced liver injury. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 28). Retrieved from https://www.asceptasm.com

Mortensen, J. S., Jensen, B. P., & Doogue, M. (2019). Determining the pre-analytical instability of beta-Lactam antibiotics in therapeutic drug monitoring samples. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 35). Retrieved from https://www.asceptasm.com

Mortensen, J. S., Jensen, B. P., & Doogue, M. (2019). Simultaneous quantification of four beta-Lactams in human plasma for therapeutic drug monitoring. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 29). Retrieved from https://www.asceptasm.com

Sinnappah, K. A., Kuan, I. H. S., Thynne, T., Doogue, M., & Wright, D. F. B. (2019). A population pharmacokinetic model for metformin in patients receiving intermittent haemodialysis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 9). Retrieved from https://www.asceptasm.com

Stamp, L., Chapman, P., Barclay, M., Horne, A., Frampton, C., Merriman, T., Wright, D., … Dalbeth, N. (2019). Relationships between allopurinol dose, oxypurinol levels and serum urate: In search of an oxypurinol therapeutic concentration. Arthritis & Rheumatology, 71(Suppl. 10), 1222. doi: 10.1002/art.41108

Stamp, L., Keating, P., Frampton, C., Barclay, M., Fanning, N., Millier, M., Hessian, P., & O'Donnell, J. (2019). Relationship between adalimumab concentrations, plasma cytokines, anti-drug antibodies and disease activity in rheumatoid arthritis. Arthritis & Rheumatology, 71(Suppl. 10), 1440. doi: 10.1002/art.41108

Walmsley, R., McCombie, A., Barclay, M., Visesio, N., Ho, C., Brown, S., Rosser, K., … Gray, A., Regenbrecht, H., Langlotz, T., & Schultz, M. (2019). A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc^® in the care of inflammatory bowel disease patients. Journal of Crohn's & Colitis, 13(Suppl. 1), (pp. S432-S433). doi: 10.1093/ecco-jcc/jjy222.754

Young, S. W., Clarke, H. D., Moore, G. A., Zhang, M., Probst, N. E., & Spangehl, M. J. (2019). Superior tissue levels of vancoymin are achieved with intraosseous versus intravenous administration despite limited tourniquet use in primary TKA: A prospective, randomized trial. Orthopaedic Proceedings, 101-B(Suppl. 11), (pp. 55). doi: 10.1302/1358-992X.2019.11.055

Maggo, S., Liau, Y., Doogue, M., & Kennedy, M. (2018). Understanding drug reactions using genome sequencing (UDRUGS) study: A New Zealand initiative to investigate the genetics of ADRs. Basic & Clinical Pharmacology & Toxicology, 123(Suppl. 1), (pp. 3). doi: 10.1111/bcpt.13020

Nichols, G., Dobbs, B., Schultz, M., Barclay, M., & Farella, M. (2018). Simultaneous monitoring of intraoral and oesophageal acidity: Is there an association? European Journal of Orthodontics, 40(5), (pp. e151). doi: 10.1093/ejo/cjy060

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Assessing for the completedness of a QSP model for azathioprine metabolism. Proceedings of the 19th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). Retrieved from http://paganz.org

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Determining the structure of a quantitative systems pharmacology (QSP) model for azathioprine metabolism. Journal of Pharmacokinetics & Pharmacodynamics, 45(Suppl. 1), (pp. S46-S47). doi: 10.1007/s10928-018-9606-9

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Internal deterministic identifiability of PK and PKPD models. Proceedings of the 19th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). Retrieved from http://paganz.org

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Arthritis & Rheumatology, 70(9, Suppl.), 2229. doi: 10.1002/art.40700

Stamp, L., Chapman, P., Barclay, M., Horne, A., Tan, P., Drake, J., & Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Scandinavian Journal of Rheumatology, 47(Suppl. 129), (pp. 40-41). doi: 10.1080/03009742.2018.1487639

Zhang, M., Moore, G., Doogue, M., & Strother, M. (2018). Simultaneous determination of the phenotyping cocktail drugs and their cytochrome P450-specific probe metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Innovation in Therapeutics. 422. Retrieved from https://www.asceptasm.com/2018-annaul-scientific-meeting

Barclay, M. L., Munning-Schmidt, E., Zhang, M., & Mulder, C. J. (2017). Late onset rise of 6-MMP metabolites in inflammatory bowel disease patients on azathioprine or mercaptopurine. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 55). Retrieved from http://www.asceptasm.com/

Chin, P. K. L., Chuah, Q., & Doogue, M. P. (2017). Vignettes from hospital-level electronic prescribing data. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 58). Retrieved from http://www.asceptasm.com/

Chin, P., Crawford, A., Chuah, Q., & Doogue, M. (2017). Impact of locally customised "blodd thinner" alerts in MedChart™. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 50). Retrieved from http://www.hinz.org.nz/

Chuah, Q., Chin, P., Hamilton, N., Gardiner, S., Strother, M., Dalton, S., Metcalf, S., & Doogue, M. (2017). Using electronic prescribing data to direct antimicrobial stewardship. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 107). Retrieved from http://www.hinz.org.nz/

Crawford, A., Chin, P., & Doogue, M. (2017). Antithrombotic drug-drug interaction alerts in MedChart™. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 48). Retrieved from http://www.asceptasm.com/

Doogue, M., Crawford, A., Miller, H., Drennan, P., Chuah, Q., Strowther, M., & Chin, P. (2017). Evidenced based drug-drug interaction alerts in an E-prescribing system. Clinical Therapeutics, 39(8, Suppl.), (pp. e18). doi: 10.1016/j.clinthera.2017.05.058

Doogue, M., McGowan, A., Barclay, M., & Jardine, D. (2017). Multimorbidity, guidelines and polypharmacy. Clinical Therapeutics, 39(8, Suppl.), (pp. e17-e18). doi: 10.1016/j.clinthera.2017.05.055

Doogue, M., McNeill, R., Pugh, S., Sylevych, V., Wilkinson, J., & Young, M. (2017). Making adverse drug reactions visible. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 61). Retrieved from http://www.hinz.org.nz/

Doogue, M., McNeill, R., Young, M., Wilkinson, J., Pugh, S., Sylevych, V., … Chuah, Q., Hamilton, N., Chua, I., … Barclay, M., & Chin, P. (2017). Making adverse drug reactions visible. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 49). Retrieved from http://www.asceptasm.com/

Doogue, M., Morahan, M.-C., Coberger, E., & Chin, P. (2017). Severe cutaneous adverse reactions and the (in)accuracy of medicines information sources. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 50). Retrieved from http://www.asceptasm.com/

Hamilton, N., Chuah, Q., Chin, P., & Gardiner, S. (2017). Real-time review of electronic prescribing of restricted antimicrobials: A pilot of a new antimicrobial stewardship initiative for Christchurch Hospital. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 79). Retrieved from http://www.asceptasm.com/

Kennedy, M. A., Maggo, S. D. S., Foulds, J., Luty, S., Chua, E. W., Cree, S., Ton, K., Liau, Y., Miller, A. L., Chin, P., … Doogue, M. (2017). DNA banking and genetic analysis of adverse drug reactions in the New Zealand healthcare setting. Proceedings of the American Society of Human Genetics (ASHG) Annual Meeting. 2123. Retrieved from http://www.ashg.org/2017meeting/

Leggett, C., Anderson, J., Couper, J., Doogue, M., Giles, L., & Pena, A. S. (2017). Metformin levels and adherence in children and adolescents with Type 1 diabetes enrolled in a 12 month randomised controlled trial. Hormone Research in Paediatrics, 88(Suppl. 1), (pp. 610-611). doi: 10.1159/000481424

McCombie, A., Walmsley, R., Barclay, M., Visesio, N., Ho, C., Brown, S., … Inns, S., & Schultz, M. (2017). Adherence and usability of the smartphone apps IBDsmart and IBDoc©. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 42. Retrieved from http://gastro2017.co.nz

McNeill, R., & Doogue, M. (2017). Pitfalls with medication safety data. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 72). Retrieved from http://www.hinz.org.nz/

McNeill, R., Chin, P., Coberger, E., & Doogue, M. (2017). A randomised controlled trial of patient information leaflets as a medication counselling tool. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 77). Retrieved from http://www.asceptasm.com/

Nichols, G., Farella, M., Dobbs, B., Schultz, M., & Barclay, M. (2017). Cross-correlation analysis of intra-oral and esophageal pH in patients with gastro-esophageal reflux disorder (GORD): A pilot study. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 56. Retrieved from http://gastro2017.co.nz

O'Donnell, J., Liu, J., Keating, P., Hock, B., Spellerberg, M., Barclay, M., & Stamp, L. (2017). Anti-drug antibodies (ADA): Assay performance in patients treated for inflammatory bowel and rheumatic disease with biodrugs, adalimumab and infliximab. Internal Medicine Journal, 47(Suppl. 2), (pp. 15). doi: 10.1111/imj.13426

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6mg/Dl: An open label extension study. Arthritis & Rheumatology, 69(Suppl. 10), 1105. doi: 10.1002/art.40321

Wright, D. F. B., Phipps-Green, A., Merriman, T. R., Barclay, M. L., Dalbeth, N., & Stamp, L. K. (2017). The influence of ABCG2 genotype on allopurinol dose predictions. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 55). Retrieved from http://www.asceptasm.com/

Young, S. W., Clarke, H. D., Moore, G. A., Zhang, M., & Spangehl, M. J. (2017). Higher tissue concentrations of vancomycin are achieved with intraosseous versus intravenous administration in revision TKA. Knee, 24(6), (pp. XIV). doi: 10.1016/j.knee.2017.08.045

Zhang, M., Moore, G. A., Doogue, M. P., & Barclay, M. L. (2017). Simultaneous determination of adalimumab and infliximab in human serum by liquid chromatography/tandem mass spectrometry. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 60). Retrieved from http://www.asceptasm.com/

Barclay, M. L. (2016). Monitoring of monoclonal antibody drugs. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 24). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Borrie, T. L., Morahan, M.-C., Barclay, M. L., Vella-Brincat, J. W. A., & McQueen, G. P. (2016). Comparison of enquiries for complementary and alternative medicines with enquiries for conventional medicines at the Medicines Information Service at Christchurch Hospital from 2010 to 2016. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 534. Retrieved from http://www.asceptasm.com/

Chuah, Q., Chin, P. K. L., Vella-Brincat, J., Strother, R. M., Lodge, C., Dean, K., & Doogue, M. P. (2016). Drug-drug interaction and brand-prescribing alerts in an electronic prescribing and administration (ePA) system. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 536. Retrieved from http://www.asceptasm.com/

Chuah, Q., Doogue, M., Strother, M., & Watson, A. (2016). Data extraction from an electronic prescribing and administration system. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 64). Retrieved from http://www.hinz.org.nz/

Chuah, Q., Vella-Brincat, J., Chin, P., Barclay, M., & Doogue, M. (2016). Use of clinical decision support in ePrescribing to facilitate generic prescribing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 20). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Coberger, E., Doogue, M., Ambrose, C., & Morahan, M.-C. (2016). Patient information leaflets: The digital transformation to MyMedicines. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 65). Retrieved from http://www.hinz.org.nz/

Doogue, M. P. (2016). ePrescribing: The devil is in the detail. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 404. Retrieved from http://www.asceptasm.com/

Doogue, M. P., Chin, P., Strother, R. M., Lodge, C., Dean, K., & Hamilton, N. (2016). Clinical decision support in an electronic prescribing and administration system. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 14). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Doogue, M., Chin, P., Strother, M., Dean, K., Lodge, C., & Hamilton, N. (2016). Evidence based clinical decision support for e-prescribing and administration to reduce alert fatigue. Proceedings of the Health Informatics New Zealand (HiNZ) Conference. (pp. 70-71). Retrieved from http://www.hinz.org.nz/

Drennan, P., Chin, P., Strother, M., Lodge, C., Dean, K., & Doogue, M. P. (2016). Drug-drug interaction alerts in an electronic prescribing system. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 16). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Gardiner, S. J., Drennan, P. G., Begg, R., Zhang, M., Green, J. K., Isenman, H. L., Everts, R. J., Chambers, S. T., & Begg, E. J. (2016). Taking flucloxacillin with food does not compromise effective plasma concentrations in healthy volunteers. Proceedings of the Australasian Society for Infectious Diseases New Zealand Branch Annual Scientific Meeting. Retrieved from https://www.asid.net.au/

Hamilton, N., Barclay, M. L., & Doogue, M. P. (2016). Diagnosing and recording adverse drug reactions in general medical patients, a cross-sectional study. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 419. Retrieved from http://www.asceptasm.com/

Hamilton, N., Barclay, M. L., & Doogue, M. P. (2016). Diagnosing and recording adverse drug reactions in general medical patients: A cross-sectional study. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 30). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Keating, P., Hock, B., Barclay, M., Stamp, L., Spellerberg, M., & O'Donnell, J. (2016). Application of an ELISA based competitive binding assay to measure concentration of anti-TNF biologics and neutralising anti-drug antibodies in the clinical laboratory. European Journal of Immunology, 46(Suppl. 1), (pp. 1033). doi: 10.1002/eji.201670200

Keating, P., Zhang, M., & Hock, B. D. (2016). Measurement of anti-TNF biologics and anti-drug antibodies in the clinical laboratory. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 22). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Martin, J., Hilmer, S., Doogue, M., Soon, J., & Brett, J. (2016). High risk, poor evidence, often futile: Using EVOLVE to rank pharmacological treatments. Proceedings of the National Medicines Symposium. 370, (pp. 158). Retrieved from http://www.nps.org.au/about-us/what-we-do/campaigns-events/national-medicines-symposium

Wareing, T. R., Chin, P., Strother, R. M., Vella Brincat, J., Chuah, Q., & Doogue, M. P. (2016). Adverse drug reactions in an electronic prescribing and administration system. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 20). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2016). Predicting oxypurinol exposure in patients receiving intermittent haemodialysis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 48). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Zhang, M., Moore, G. A., & Chin, P. (2016). Simultaneous determination of dabigatran, rivaroxaban and apixaban in human plasma by liquid chromatography/tandem mass spectrometry. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 552. Retrieved from http://www.asceptasm.com/

Allison, J., Vella-Brincat, J., & Doogue, M. P. (2015). Laxative co-prescribing with opioids on discharge from Christchurch hospitals. Proceedings of the New Zealand Hospital Pharmacists' Association (NZHPA) Annual Conference. (pp. 82). Retrieved from http://www.nzhpa.org.nz/conferences--meetings.aspx

Barclay, M. L., Jalilzadeh, A., Vajjah, P., & Duffull, S. (2015). A mathematical model of the metabolic pathway for azathioprine and 6-mercaptopurine. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 158. Retrieved from http://www.asceptasm.com/

Borrie, T. L., Young, M. L., Vella-Brincat, J. W. A., Doogue, M. P., & Pickering, J. W. (2015). Medication errors in patients undergoing elective surgery. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 511. Retrieved from http://www.asceptasm.com/

Buffery, P. J., Metcalf, S., & Doogue, M. P. (2015). Cerebrospinal fluid pharmacokinetics of tobramycin following intraventricular administration. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 235. Retrieved from http://www.asceptasm.com/

Chew-Harris, J. S. C., Chin, P. K. L., Florkowski, C. M., George, P. M., & Endre, Z. H. (2015). Accounting for individual body surface area does improve estimation of absolute GFR using the CKD-EPI equation. Pathology, 47(Suppl. 1), (pp. S82). doi: 10.1097/01.PAT.0000461557.00460.df

Chin, P. K. L., Drennan, P. G., Dalton, S. C., Zhang, M., & Begg, E. J. (2015). Flucloxacillin: Total concentrations poorly reflect unbound concentrations in hospitalised patients. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 236. Retrieved from http://www.asceptasm.com/

Doogue, M. P. (2015). The mis-diagnosis of adverse drug reactions. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 306. Retrieved from http://www.asceptasm.com/

Drennan, P., Chin, P., Strother, M., Lodge, C., Dean, K., & Doogue, M. (2015). Drug-drug interaction alerts in an electronic prescribing system. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 164. Retrieved from http://www.asceptasm.com/

Kannangara, D., Graham, G., Wright, D., Barclay, M., Stamp, L., Williams, K., & Day, R. (2015). Treating gout patients with allopurinol: A concentration- or dose-response approach? Internal Medicine Journal, 45(Suppl. 2), (pp. 13). doi: 10.1111/imj.12752

McGowan, A., Jardine, D. L., Barclay, M. L., & Doogue, M. P. (2015). Complex patients, polypharmacy and guidelines. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 525. Retrieved from http://www.asceptasm.com/

Polasek, T. M., Thynne, T. R., & Doogue, M. P. (2015). Metformin in pregnant women with type 2 diabetes mellitus: Update on safety and efficacy. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 530. Retrieved from http://www.asceptasm.com/

Smith, M. M., Vella-Brincat, J., Robertshawe, B., & Doogue, M. P. (2015). The incidence of hospitalisation due to medicine induced rhabdomyolysis. Proceedings of the New Zealand Hospital Pharmacists' Association (NZHPA) Annual Conference. (pp. 93). Retrieved from http://www.nzhpa.org.nz/conferences--meetings.aspx

Thompson, A., Roberts, S., Cheng, W., Angus, P., Visvanathan, K., Iyer, R., & Barclay, M. (2015). SB 9200, A novel immunomodulator for patients with viral hepatitis: Phase 1 MAD Study in patients with hepatitis C virus (HCV) infection. Journal of Hepatology, 62(Suppl. 2), (pp. S283-S284). doi: 10.1016/S0168-8278(15)30194-X

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Barclay, M. L., & Stamp, L. K. (2015). Allopurinol dosing in patients with renal impairment. Proceedings of the Twenty-Fourth Annual Meeting of the Population Approach Group in Europe (PAGE). 3338. Retrieved from http://www.page-meeting.org/

Zhang, M., Moore, G. A., Everts, R., & Begg, E. J. (2015). Determination of total and free concentrations of cefalexin, cefazolin, flucloxacillin and probenecid in human plasma by liquid chromatography/tandem mass spectrometry. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 535. Retrieved from http://www.asceptasm.com/

Barclay, M. L., Helms, E., Hock, B., Schultz, M., & Stamp, L. K. (2014). Trough concentrations of infliximab and adalimumab, and anti-drug antibodies, correlate with drug response in inflammatory bowel disease. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 25). Retrieved from http://www.asceptasm.com/

Polasek, T. M., Snyder, B. D., Rowland, A., Miners, J. O., & Doogue, M. P. (2014). In vivo evaluation of felodipine as an inhibitor of cytochrome P450 enzymes and P-glycoprotein. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 44). Retrieved from http://www.asceptasm.com/

Vella-Brincat, J., Kortegast, A., & Doogue, M. (2014). Oxycodone and other analgesics prescribing on discharge from Christchurch Hospital. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 46). Retrieved from http://www.asceptasm.com/

Wright, D. F. B., Merriman, T. R., Duffull, S. B., Barclay, M. L., & Stamp, L. K. (2014). The relationship between fractional urate clearance and renal transporter genotype in patients with gout. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 47). Retrieved from http://www.asceptasm.com/

Huelsen, A., Fischer, J., Hegarty, J., Lim, J. Y., Burnside, M. J., Karim, S. N., Onyango, N., Frampton, C., Spencer, A. J., & Barclay, M. L. (2013). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is more effective for young trainees: A randomised controlled study. Internal Medicine Journal, 43(Suppl. 3), (pp. 16). doi: 10.1111/imj.12149

Barclay, M. L. (2012). Practical experiences of 3 decades of TDM/TCI in Christchurch. Proceedings of the Medical Sciences Congress (MedSci). (pp. 7). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf

Begg, E. J., Chin, P. K. L., Allen, K., & Buffery, P. (2012). Economising on busulphan samples for concentration monitoring during intravenous therapy. Proceedings of the Medical Sciences Congress (MedSci). (pp. 41). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf

Buffery, P., Chin, P. K. L., & Begg, E. J. (2012). Gentamicin dosing: Musings from the higher end. Proceedings of the Medical Sciences Congress (MedSci). (pp. 41-42). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf

Chin, P. K. L., Barclay, M. L., & Begg, E. J. (2012). Dose individualisation of Dabigatrin. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 33). Retrieved from http://www.ascept-apsa.com/

Chin, P. K. L., Florkowski, C. M., & Begg, E. J. (2012). The performance of the Cockcroft-Gault, MDRD and CKD-EPI equations in predicting gentamicin clearance. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 43). Retrieved from http://www.ascept-apsa.com/

Huelsen, A., Fischer, J., Hegarty, J., Lim, J. Y., Burnside, M. J., Karim, S. N., Onyango, N., Frampton, C., Spencer, A. J., & Barclay, M. L. (2012). The Scratch Test for identifying the lower liver edge is at least as accurate as percussion and is more effective for trainees: A randomized controlled study. New Zealand Medical Journal, 125(1367). Retrieved from http://www.nzma.org.nz/journal

Kumar, S. S., Wong, C., Graham, G. G., Begg, E. J., Chin, P. K. L., Brett, J., … Day, R. (2012). Gentamicin directed therapy: Which program to use? Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 56). Retrieved from http://www.ascept-apsa.com/

Stamp, L. K., Khalilova, I., Zhang, M., Turner, R., & Kettle, A. (2012). Oxidation of urate to allantoin by myeloperoxidase in gout. Arthritis & Rheumatism, 64(10, Suppl.), (pp. S808). doi: 10.1002/art.37735

Vella-Brincat, J., Begg, E., & Chin, P. (2012). The use of plasma creatinine concentrations as a measure of drug induced kidney failure. Proceedings of the Medical Sciences Congress (MedSci). (pp. 53). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2012). The population pharmacokinetics of allopurinol and oxypurinol. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 55). Retrieved from http://www.ascept-apsa.com/

Barclay, M. L., Van Egmond, R., Chin, P. K. L., & Mulder, C. J. J. (2011). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 7.4. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Begg, E. J., Plajer, S. M., Chin, P. K. L., Vella-Brincat, J. W. A., & Buffery, P. (2011). Extended-interval gentamicin dosing in adult patients with impaired renal function: Should the dose interval be extended further? Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 2.5. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Buffery, P., Begg, E., Barclay, M., & Moore, G. (2011). A retrospective pharmacokinetic review of the busulphan monitoring service at Christchurch Hospital. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 4.5. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Chin, P. K. L., & Begg, E. J. (2011). The performance of GFR formulae for estimating gentamicin clearance. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 1.2. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Journal of Translational Medicine, 8(Suppl. 1), P2. doi: 10.1186/1479-5876-8-S1-P2

Eglinton, T. W., Roberts, R. L., Pearson, J. F., Barclay, M. L., Ferguson, L. R., Han, D. Y., Frizelle, F. A., & Gearry, R. B. (2011). Clinical and genetic risk factors for perianal Crohn's disease (CD) in a population based cohort. Colorectal Disease, 13(Suppl. s5), 067, (pp. 12). doi: 10.1111/j.1463-1318.2011.02655.x

Jensen, B. P., Vella-Brincat, J. W. A., Chin, P. K. L., Roberts, R. L., & Begg, E. J. (2011). An LC-MS/MS assay for quantification of cyclizine and norcyclizine in a pharmacokinetic study of subcutaneous cyclizine in palliative care patients. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) - Australian Physiological Society (AuPS) - High Blood Pressure Research Council of Australia (HBPRCA) Joint Meeting. Retrieved from http://ascept2011.eproceedings.com.au/papers/p17.pdf

Jensen, B. P., Zhang, M., Moore, G., & Begg, E. J. (2011). LC-MS in clinical pharmacology and toxicology: From niche projects to routine screening. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 6.3. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Patel, F., Jensen, B. P., Doogue, M. P., & Polasek, T. M. (2011). Effects of adult age on predicted total drug clearance. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) - Australian Physiological Society (AuPS) - High Blood Pressure Research Council of Australia (HBPRCA) Joint Meeting. Retrieved from http://ascept2011.eproceedings.com.au/papers/p5.pdf

Stamp, L. K., Chapman, P. T., Barclay, M., Kremer, J. M., & Dervieux, T. (2011). Red blood cell folate polyglutamates are an important determinant of RA disease activity in patients on Methotrexate: Implications for folic acid supplementation. Arthritis & Rheumatism, 63(Suppl. 10), (pp. S961-S962). doi: 10.1002/art.33310

Vella-Brincat, J. W. A., Begg, E. J., Jensen, B. P., Chin, P. K. L., Roberts, R. L., Fairhall, M., MacLeod, S. A. D., … Walker, J. (2011). The pharmacokinetics of the antiemetic cyclizine, and how it feels to be subjected to blood sample orientated research, in palliative care. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 4.3. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2011). Determination of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in human red blood cells by LC-MS/MS. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 7.2. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2010). Effects of changing from oral to subcutaneous administration of methotrexate on RBC MTX polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Begg, E. J., Zhang, M., & Bird, P. A. (2010). Intratympanic versus intravenous delivery of dexamethasone into cochlear perilymph compared with plasma. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Doecke, J., Simms, L. A., Zhao, Z. Z., Huang, N., Hanigan, K., Croft, A., … Roberts, R. L., … Barclay, M. L., … Gearry, R. B., … Radford-Smith, G. L. (2010). Genetic susceptibility in IBD: Overlap between ulcerative colitis and Crohn's disease. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A84). doi: 10.1111/j.1440-1746.2010.06454.x

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2010). Gene-gene interaction between Macrophage Migration Inhibitory Factor (MIF) and NOD2 alters susceptibility to ileal Crohn's disease. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Gearry, R. B., Glubb, D. M., Hollis-Moffatt, J. E., Topless, R. K. G., Simms, L. A., Doecke, J. D., … Barclay, M. L., … Merriman, T. R., … Roberts, R. L. (2010). Extracellular matrix protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A80). doi: 10.1111/j.1440-1746.2010.06454.x

Glubb, D. M., Pearson, J., Hollis-Moffatt, J. E., Topless, R. K. G., Merriman, T. R., Simms, L. A., … Barclay, M. L., … Gearry, R. B., … Roberts, R. L. (2010). Extracellular Matrix Protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Huelsen, A., & Barclay, M. L. (2010). Balloon dilatation in achalasia is effective and safe: A 13-year single centre experience. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Jensen, B. P., Chin, P. K. L., Roberts, R. L., & Begg, E. J. (2010). Total and free clearance of R- and S-warfarin in elderly people. Proceedings of the 44th Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. Retrieved from http://ascept.eproceedings.com.au/papers/p76.pdf

Jensen, B. P., Chin, P., Roberts, R. L., & Begg, E. J. (2010). Total and free clearance of R- and S-warfarin in elderly people. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Jensen, B. P., Chin, P., Roberts, R. R., Maddison, J., & Begg, E. J. (2010). Total and free clearance of R- and S-warfarin in elderly people. Basic & Clinical Pharmacology & Toxicology, 107(Suppl. 1), (pp. 354-355). doi: 10.1111/j.1742-7843.2010.00600.x

Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x

Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Population-based epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x

Patel, D., Vella-Brincat, J., Chin, P., Jensen, B., & Begg, E. (2010). Is frailty associated with impaired drug clearance in the elderly? Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Roberts, R. L., Gearry, R. B., & Barclay, M. L. (2010). Are there pharmacogenetic indicators for allopurinol combination therapy in inflammatory bowel disease? Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Roberts, R. L., Gearry, R. B., Barclay, M. L., Hollis-Moffatt, J. E., Merriman, T. R., Jenks, K., Schultz, M., & Stebbings, S. (2010). Specific Interleukin-23 receptor haplotype may confer protection against Crohn's disease while increasing risk of Spondyloarthritis. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Simms, L. A., Doecke, J., Huang, N., Zhao, Z. Z., Kristine, F. U., Roberts, R. L., Barclay, M. L., … Gearry, R. B., & Radford-Smith, G. L. (2010). Genotype markers predict time to first resection in Crohn's disease patients. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A82-A83). doi: 10.1111/j.1440-1746.2010.06454.x

Stamp, L. K., O'Donnell, J. L., Chapman, P., Zhang, M., James, J., Frampton, C., & Barclay, M. (2010). The effect on MTX polyglutamate concentration profile after changing from oral to subcutaneous methotrexate in rheumatoid arthritis. Arthritis & Rheumatism, 62(Suppl. 10). doi: 10.1002/art.30166

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2010). Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Barclay, M. L., Roberts, R. L., & Gearry, R. B. (2009). Using genetics of inflammatory bowel disease to develop new treatments: A different slant on pharmacogenetics. Proceedings of the 5th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.otago.ac.nz/christchurch/otago019049.pdf

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., & James, J. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term methotrexate. In D. Hay & S. Ngo (Eds.), Proceedings of the 43rd Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 14. ASCEPT. [Abstract]

Begg, E., Chin, P., Svensson, A., & Davis, N. (2009). From pharmacogenetics to drug interactions. Proceedings of the 5th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.otago.ac.nz/christchurch/otago019049.pdf

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2009). Meta-analysis provides no evidence for glioma-associated oncogene homolog 1 as a risk factor for inflammatory bowel disease in Caucasians. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2009). Association of increased beta-defensin 2 genomic copy number with Crohn's disease. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Glubb, D. M., Hollis-Moffatt, J. E., Topless, R. K. G., Gearry, R. B., . . ., Barclay, M. L., … Merriman, T. R., … Roberts, R. L. (2009). Extracellular Matrix Protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Roberts, R. L., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., Kennedy, M. A., Barclay, M. L., & Stamp, L. K. (2009). Genetic polymorphisms in the folate pathway predict red blood cell folate concentrations but not methotrexate response in rheumatoid arthritis. Proceedings of the 5th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.otago.ac.nz/christchurch/otago019049.pdf

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of methotrexate red blood cell polyglutamates in patients with rheumatoid arthritis on long-term MTX. Internal Medicine Journal, 39(Suppl. 2), (pp. A43). doi: 10.1111/j.1445-5994.2009.01951_1.x

Stamp, L. K., O'Donnell, J. L., Zhang, M., Frampton, C., James, J., Barclay, M., & Chapman, P. T. (2009). Relationship between allopurinol dose, plasma oxypurinol concentration and serum urate. Internal Medicine Journal, 39(Suppl. 2), (pp. A43). doi: 10.1111/j.1445-5994.2009.01951_1.x

Stamp, L., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., Barclay, M., Kennedy, M., & Roberts, R. (2009). Functional polymorphisms within the folate pathway predict red blood cell folate concentrations but are not associated with methotrexate response in RA. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S150). doi: 10.1002/art.27423

Stamp, L., O'Donnell, J. L., Zhang, M., Frampton, C., Barclay, M., & Chapman, P. T. (2009). Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including in those with renal impairment: A pilot study. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S729). doi: 10.1002/art.27423

Stamp, L., O'Donnell, J. L., Zhang, M., Frampton, C., Chapman, P. T., & Barclay, M. (2009). Relationship between serum urate and plasma oxypurinol: Is there a target plasma oxypurinol concentration to achieve serum urate ≤6mg/dL. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S561). doi: 10.1002/art.27423

Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology. 23(Suppl. 4), (pp. A194). [Abstract]

Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavourable metabolite ratio. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf

Chalmers-Watson, T. A., Tarrant, K. M., Barclay, M., Shirley, P. M., Frampton, C. M. A., & Gearry, R. B. (2008). Prevalence of extra-intestinal manifestations of inflammatory bowel disease in a population-based cohort. Journal of Gastroenterology & Hepatology, 23(Suppl. 4), (pp. A221). doi: 10.1111/j.1440-1746.2008.05611.x

Dalrymple, J., Stamp, L. K., O'Donnell, J., Chapman, P., Zhang, M., & Barclay, M. (2008). Pharmacokinetics of oral MTX in RA patients. Arthritis & Rheumatism, 58(Suppl.9), (pp. S311). [Abstract]

Frizelle, F., Barclay, M., & Gearry, R. (2008). Characteristics of resectional surgery in a population-based inflammatory bowel disease cohort. Diseases of the Colon & Rectum. 51(5), (pp. 671). doi: 10.1007/s10350-008-9314-4

Frizelle, F., Gearry, R., & Barclay, M. (2008). Surgery for perianal disease in a population-based Crohn's disease cohort. Diseases of the Colon & Rectum. 51(5), (pp. 669). doi: 10.1007/s10350-008-9314-4

Gearry, R. B., Roberts, R. L., Kennedy, M. A., Zhang, M., & Barclay, M. L. (2008). Thiopurine metabolites, intermediate steps on the way to complete thiopurine pharmacogenetics. Proceedings of the 4th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Gearry, R. B., Tarrant, K. M., Shirley, P. M., Frampton, C. M., & Barclay, M. L. (2008). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of inflammatory bowel disease phenotype. Journal of Gastroenterology & Hepatology, 23(Suppl. 4), (pp. A178). doi: 10.1111/j.1440-1746.2008.05610.x

Roberts, R. L., Gearry, R. B., Zhang, M., Begg, E. J., & Barclay, M. L. (2008). Optimisation of methotrexate in inflammatory bowel disease patients. Proceedings of the 4th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Stamp, L. K., O'Donnell, J., Chapman, P., Zhang, M., Frampton, C., & Barclay, M. (2008). Methotrexate polyglutamates and disease activity in rheumatoid arthritis. Arthritis & Rheumatism, 58(Suppl. 9), (pp. S544). [Abstract]

Zhang, M., Moore, G. A., Banks, J. C., Rogers, G. R., & Begg, E. J. (2008). HPLC assay for the determination of nortriptyline and its hydroxylated metabolites in plasma. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf

Barclay, M. L., Ailabouni, R., & Gearry, R. B. (2007). Complementary and alternative medicine use in IBD is determined by age, sex and socioeconomic status and is no different than in controls without IBD. Gut. 56(Suppl. III), (pp. A151). [Abstract]